<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gabapentin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gabapentin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gabapentin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12504" href="/d/html/12504.html" rel="external">see "Gabapentin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13330" href="/d/html/13330.html" rel="external">see "Gabapentin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F175023"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gralise;</li>
<li>Neurontin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867008"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Gabapentin;</li>
<li>APO-Gabapentin;</li>
<li>Auro-Gabapentin;</li>
<li>BIO-Gabapentin [DSC];</li>
<li>DOM-Gabapentin;</li>
<li>GD-Gabapentin [DSC];</li>
<li>GLN-Gabapentin;</li>
<li>JAMP-Gabapentin;</li>
<li>Mar-Gabapentin;</li>
<li>MINT-Gabapentin;</li>
<li>Neurontin;</li>
<li>PMS-Gabapentin;</li>
<li>Priva-Gabapentin [DSC];</li>
<li>PRO-Gabapentin;</li>
<li>RAN-Gabapentin [DSC];</li>
<li>RIVA-Gabapentin;</li>
<li>TARO-Gabapentin [DSC];</li>
<li>TEVA-Gabapentin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F175060"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous;</li>
<li>
                        GABA Analog</li></ul></div>
<div class="block doa drugH1Div" id="F175027"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> For patients with respiratory disease, initiate therapy at the lowest dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9192803-8b96-41ab-8488-f36d16324eb4">Alcohol use disorder, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Gabapentin is suggested by some experts as an alternative when first-line agents cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Johnson.2018','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Johnson.2018','lexi-content-ref-VADOD.1'])">Ref</a></span>). Gabapentin may be misused by some patients with substance use disorders; evaluate for risk and signs of addiction and dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26721643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26721643'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 300 mg once daily; increase dose based on response and tolerability in increments of 300 mg every 1 to 2 days up to a target dose of 600 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18540923','lexi-content-ref-24190578','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18540923','lexi-content-ref-24190578','lexi-content-ref-VADOD.1'])">Ref</a></span>). Some experts consider alternative therapy if goals are not met within 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9679052-03a5-40df-ba72-b799a014c1cc">Alcohol withdrawal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol withdrawal (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Withdrawal will progress at different rates in some patients; flexibility in dosing and duration is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.2018','lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.2018','lexi-content-ref-VADOD.1'])">Ref</a></span>). Regimens vary and depend on withdrawal history, degree of current withdrawal symptoms, quantity of alcohol consumption, concomitant medications for breakthrough symptoms, and whether the patient is treated inpatient or in the ambulatory setting. For example, in an inpatient study that enrolled patients with Clinical Institute Withdrawal Assessment (CIWA) scores &gt;15 and offered no as-needed medications for breakthrough withdrawal symptoms, 3.2 g in divided doses was offered on day 1 of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20019070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20019070'])">Ref</a></span>). Many facilities only treat alcohol withdrawal in the ambulatory setting if CIWA score is ≤15 and there is no history of withdrawal seizures or delirium tremens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.2018','lexi-content-ref-33224688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.2018','lexi-content-ref-33224688'])">Ref</a></span>). The following are two suggested regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CIWA score &lt;10</i>: Immediate release<b>: Oral: </b>Initial: 300 mg every 6 hours on day 1, then 300 mg every 8 hours on day 2, then 300 mg every 12 hours on day 3, then 300 mg at night on day 4. In addition to scheduled doses, provide one additional as-needed 300 mg dose per day for breakthrough withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CIWA score 10 to 18 (alternative agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109'])">Ref</a></span>)</i>: Immediate release: <b>Oral:</b> Initial: 300 to 400 mg 3 times daily on days 1 through 3, then 300 to 400 mg twice daily on day 4, then discontinue. For breakthrough symptoms during days 1 through 4, consider providing single doses of 100 mg, which may be administered up to 3 times daily, and a 300 mg dose reserved for the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19485969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19485969'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63eca950-fb2d-4d31-9e25-43026567d145">Cough, chronic refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough, chronic refractory (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with cough lasting &gt;8 weeks who have had negative responses to treatments for asthma, gastroesophageal reflux disease, and rhinitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22951084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22951084'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 300 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26426314','lexi-content-ref-22951084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26426314','lexi-content-ref-22951084'])">Ref</a></span>); if significant somnolence develops, some experts recommend decreasing dose to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberger.1'])">Ref</a></span>). May increase dose gradually based on response and tolerability in increments of 300 mg to a maximum dose of 900 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26426314','lexi-content-ref-22951084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26426314','lexi-content-ref-22951084'])">Ref</a></span>). Re-evaluate therapeutic need after 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26426314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26426314'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ad982f6-abe6-4e23-89e9-30b803d922e2">Fibromyalgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who do not respond to or tolerate preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2018'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 100 to 300 mg once daily at bedtime; increase dose gradually based on response and tolerability every 1 to 2 weeks to a target dose of 1.2 to 2.4 g/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17393438','lexi-content-ref-Goldenberg.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17393438','lexi-content-ref-Goldenberg.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adjunctive therapy for short-term symptom relief until concurrent therapy is effective (eg, 4 to 6 weeks, followed by tapering). Long-term augmentation may be considered when preferred treatments (eg, serotonin reuptake inhibitors) are partially effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral: </b>Initial: 300 mg/day; may increase dose every ≥3 days based on response and tolerability up to 2.4 g/day, in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.2021','lexi-content-ref-33424664','lexi-content-ref-23053645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.2021','lexi-content-ref-33424664','lexi-content-ref-23053645'])">Ref</a></span>). <b>Note: </b>In patients sensitive to side effects, some experts suggest a lower starting dose of 100 mg/day and more gradual titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="537d7c90-6631-4ce0-b2a7-9d4ee947be4f">Hiccups</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hiccups (singultus) (off-label use</b>
<b>):</b> Immediate release: <b>Oral:</b> Usual dose range: 300 mg to 1.2 g/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15308440','lexi-content-ref-17360149','lexi-content-ref-14998440','lexi-content-ref-14581957','lexi-content-ref-18090442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15308440','lexi-content-ref-17360149','lexi-content-ref-14998440','lexi-content-ref-14581957','lexi-content-ref-18090442'])">Ref</a></span>). Can be discontinued the day after hiccups subside; long-term therapy may be warranted for persistent or relapsing hiccups (eg, palliative care) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lembo.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lembo.2018'])">Ref</a></span>). <b>Note:</b> In patients with refractory hiccups, may use in combination with a proton pump inhibitor, baclofen, or metoclopramide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28759492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28759492'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="393e56f7-bded-45b3-b486-3009d2e7543b">Neuropathic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing recommendations (for other than postherpetic neuralgia) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For chronic use, an adequate trial with gabapentin may require 2 months or more (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12373695','lexi-content-ref-Tauben.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12373695','lexi-content-ref-Tauben.2020'])">Ref</a></span>). For critically ill patients with neuropathic pain, gabapentin may be a useful component of multimodal pain control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 100 to 300 mg 1 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27999003','lexi-content-ref-24938318','lexi-content-ref-21745832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27999003','lexi-content-ref-24938318','lexi-content-ref-21745832'])">Ref</a></span>); increase dose based on response and tolerability to a target dose range of 300 mg to 1.2 g 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21482920','lexi-content-ref-27999003','lexi-content-ref-20402746','lexi-content-ref-25575710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21482920','lexi-content-ref-27999003','lexi-content-ref-20402746','lexi-content-ref-25575710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: 300 mg at bedtime; increase dose based on response and tolerability to a target dose of 900 mg to 3.6 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25575710','lexi-content-ref-22497967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25575710','lexi-content-ref-22497967'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd263141-59d9-4f4b-8e26-25d16a66c401">Postherpetic neuralgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> 300 mg once on day one, 300 mg twice daily on day 2, and 300 mg 3 times daily on day 3, then increase as needed up to 1.8 to 3.6 g/day in divided doses. Additional benefit of doses &gt;1.8 g/day has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Initial: 300 mg once daily; increase by 300 mg each day up to 900 mg once daily. Further increase as needed up to 1.8 g once daily. Additional benefit of doses &gt;1.8 g/day has not been established.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6545edec-78ea-47f0-a591-2f6ccea5471b">Pruritus, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus, chronic (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b> For patients with pruritus resistant to preferred therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27206757','lexi-content-ref-22790094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27206757','lexi-content-ref-22790094'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neuropathic (eg, brachioradial pruritus, notalgia paresthetica) or malignancy-related pruritus: </i>Immediate release: <b>Oral:</b> Initial: 300 mg/day in 1 to 3 divided doses; increase dose based on response and tolerability up to 1.8 g/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16709503','lexi-content-ref-15099389','lexi-content-ref-20629833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16709503','lexi-content-ref-15099389','lexi-content-ref-20629833'])">Ref</a></span>). Higher doses up to 3.6 g/day have been used in oncology populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16908377','lexi-content-ref-20948434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16908377','lexi-content-ref-20948434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uremic</i>
<i> pruritus</i>: Immediate release: <b>Oral:</b> Initial: 100 mg after dialysis on hemodialysis days; may increase dose based on response and tolerability up to 300 mg after dialysis on hemodialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15575002','lexi-content-ref-Kobrin.2018','lexi-content-ref-27043168','lexi-content-ref-19212903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15575002','lexi-content-ref-Kobrin.2018','lexi-content-ref-27043168','lexi-content-ref-19212903'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (off-label use):</b> Immediate release: <b>Oral:</b> Initial: 100 to 300 mg once daily 2 hours before bedtime; may increase dose every 1 to 2 weeks until symptom relief is achieved (range: 300 mg to 2.4 g/day). Suggested maintenance dosing schedule for doses ≥600 mg/day: One-third of total daily dose given midday, remaining two-thirds of the total daily dose given in the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12451200','lexi-content-ref-14504416','lexi-content-ref-27448465','lexi-content-ref-20049491','lexi-content-ref-Silber.2018','lexi-content-ref-16987157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12451200','lexi-content-ref-14504416','lexi-content-ref-27448465','lexi-content-ref-20049491','lexi-content-ref-Silber.2018','lexi-content-ref-16987157'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b3f1d16-f7e6-430c-b42d-73b52a9ae376">Seizures, focal onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, focal (partial) onset:</b> Immediate release: <b>Oral:</b> Initial: 300 mg 3 times daily; increase dose based on response and tolerability. Usual dosage: 300 to 600 mg 3 times daily; doses up to 2.4 g/day and 3.6 g/day have been tolerated in long-term and short-term clinical studies, respectively. Some experts recommend a lower starting dose (eg, 100 mg 3 times daily) with titration as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Monotherapy or adjunctive therapy for patients who do not tolerate or respond to preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2018'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 300 mg twice daily; increase dose based on response and tolerability in increments of no more than 300 mg/day up to a maximum of 3.6 g/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10440462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10440462'])">Ref</a></span>). Some experts recommend initiating with 100 mg 3 times daily in patients with respiratory disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 300 to 400 mg once daily at bedtime; some experts use an initial dose of 100 mg once daily to avoid adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Santen.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Santen.2018'])">Ref</a></span>); increase gradually (eg, over 3 to 12 days) based on response and tolerability up to 600 mg to 2.4 g/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24463691','lexi-content-ref-26382310','lexi-content-ref-16816054','lexi-content-ref-19302896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24463691','lexi-content-ref-26382310','lexi-content-ref-16816054','lexi-content-ref-19302896'])">Ref</a></span>). Some experts suggest gabapentin for women whose symptoms occur primarily at night and favor a maximum dose of 900 mg to 1.2 g, given as one dose at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26444994','lexi-content-ref-Santen.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26444994','lexi-content-ref-Santen.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Initial: 600 mg once daily at bedtime; increase gradually (eg, 600 mg every 3 days) to target dose of 600 mg in the morning and 1.2 g at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24149930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24149930'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy: </b></i>In patients receiving gabapentin chronically, unless safety concerns require a more rapid withdrawal, gabapentin should be withdrawn gradually over ≥1 week to minimize the potential of increased seizure frequency (in patients with epilepsy) or other withdrawal symptoms (eg, confusion, irritability, tachycardia, diaphoresis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11479399','lexi-content-ref-15898970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11479399','lexi-content-ref-15898970'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991466"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Oral:</b> Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initial doses of gabapentin should be conservative and titrated based on effectiveness and tolerability.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Gabapentin Dose Adjustments for Kidney Impairment<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Approximate Maintenance Dose Adjustment</p></th>
<th align="center">
<p style="text-indent:0em;">Maximum Maintenance Dose</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>Choose normal dose based on indication (see Adult dosing), then choose the adjusted dose from the column corresponding to the patient's CrCl.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>Expert opinion derived from Blum 1994, Davison 2014, Davison 2019, manufacturer's labeling.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup>Estimation of renal function for dosing adjustments should be done using the Cockcroft Gault formula.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;79</p></td>
<td align="center">
<p style="text-indent:0em;">No dose adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">3,600 mg/day in 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to 79</p></td>
<td align="center">
<p style="text-indent:0em;">No dose adjustment necessary, not to exceed 1,800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">1,800 mg/day in 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to 49</p></td>
<td align="center">
<p style="text-indent:0em;">~50% reduction</p></td>
<td align="center">
<p style="text-indent:0em;">900 mg/day in 2 to 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 29</p></td>
<td align="center">
<p style="text-indent:0em;">~75% reduction</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/day in 1 to 2 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15</p></td>
<td align="center">
<p style="text-indent:0em;">~90% reduction</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg/<b>day</b> in 1 dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50% over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7665723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7665723'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 100 mg 3 times per week after hemodialysis. Titrate to effect up to 300 mg 3 times per week given after hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23572323','lexi-content-ref-15575002','lexi-content-ref-Kobrin.2018','lexi-content-ref-25864854','lexi-content-ref-27043168','lexi-content-ref-19212903','lexi-content-ref-Spaia.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23572323','lexi-content-ref-15575002','lexi-content-ref-Kobrin.2018','lexi-content-ref-25864854','lexi-content-ref-27043168','lexi-content-ref-19212903','lexi-content-ref-Spaia.2009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Some experts recommend cautious titration to a maximum of 300 mg/day in select patients requiring additional pain control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30833302','lexi-content-ref-27881247','lexi-content-ref-12900801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30833302','lexi-content-ref-27881247','lexi-content-ref-12900801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 100 mg every other day. Titrate to effect up to 300 mg every other day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25864854','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25864854','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Some experts recommend cautious titration to a maximum of 300 mg/day in select patients requiring additional pain control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30833302','lexi-content-ref-27881247','lexi-content-ref-12900801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30833302','lexi-content-ref-27881247','lexi-content-ref-12900801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> CRRT:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or approximately 1,500 to 3,000 mL/hour) unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:6em;">CVVH/CVVHD/CVVHDF:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Dosing based on expert opinion; no evidence available. Pharmacokinetic characteristics and one case report suggest gabapentin is cleared by CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22279347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22279347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 100 mg twice daily and titrate to effect. Suggested maximum dose: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Follow initial dose titration schedule if treatment naive. Estimation of renal function for dosing adjustments should be done using the Cockcroft-Gault formula. Renally adjusted dose recommendations are based on doses up to 1.8 g/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CrCl ≥60 mL/minute:</b> Oral: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CrCl &gt;30 to 59 mL/minute:</b> Oral: 600 mg to 1.8 g once daily; dependent on tolerability and clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CrCl &lt;30 mL/minute:</b> Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>End-stage renal disease requiring hemodialysis:</b> Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988788"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:0em;">
<b>Note:</b> Initial doses of gabapentin should be conservative and titrated based on effectiveness and tolerability. The following recommendations are based on the use of IR formulations of gabapentin only; there are insufficient data to make dosage recommendations for the ER formulations in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Initial or dose titration in patients with preexisting liver cirrhosis</i>
<i>: </i>Note: </b>Use with caution in patients with hepatic encephalopathy, renal impairment, or concomitant use of other CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35103995','lexi-content-ref-30992804','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35103995','lexi-content-ref-30992804','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i></i></b>
<b>Child-Turcotte-Pugh class A: Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i></i></b>
<b>Child-Turcotte-Pugh class B and C: Oral:</b> Initial: ≤300 mg per day in 1 to 3 divided doses; may titrate as tolerated to the usual indication-specific maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B): </i>Note: </b>Use with caution in patients with hepatic encephalopathy, renal impairment, or concomitant use of CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35103995','lexi-content-ref-30992804','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35103995','lexi-content-ref-30992804','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New Child-Turcotte-Pugh class A:</b>
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression to Child-Turcotte-Pugh class B and C: Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Acute worsening of hepatic function (eg, requiring hospitalization):</i></b>Consider an initial 50% reduction in daily dose to mitigate signs and symptoms associated with hepatic encephalopathy; especially if patient presents with concurrent renal insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). If discontinuation of gabapentin is necessary, a more rapid taper (eg, 50% reduction in daily dose every 3 to 4 days) while hospitalized with frequent monitoring for withdrawal is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F175028"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (off-label use): </b>Immediate release: Oral: Initial: 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other indications:</b></i> Initiate therapy at the lowest dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>). Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy</b>:</i> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F175044"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13330" href="/d/html/13330.html" rel="external">see "Gabapentin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Pediatric doses presented as mg/kg/<b>day</b> and mg/kg/dose; use precaution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42dcb5f5-e8d5-4286-9bb5-f280e0e04481">Seizures, partial onset; adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, partial onset; adjunctive therapy: Note:</b> Do not exceed 12 hours between doses with 3-times-daily dosing. If gabapentin is discontinued or if another antiseizure medication is added to therapy, it should be done slowly over a minimum of 1 week.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;12 years: Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: Oral: 10 to 15 mg/kg/<b>day</b> divided into 3 doses daily; titrate dose upward over ~3 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance usual dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 3 to 4 years: Oral: 40 mg/kg/<b>day</b> divided into 3 doses daily; maximum daily dose: In one long-term study, doses up to 50 mg/kg/<b>day</b> were well-tolerated.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to &lt;12 years: Oral: 25 to 35 mg/kg/<b>day</b> divided into 3 doses daily; maximum daily dose: In one long-term study, doses up to 50 mg/kg/<b>day</b> were well-tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Immediate release: Oral: Initial: 300 mg 3 times daily; titrate dose upward if needed; usual maintenance dose: 900 to 1,800 mg/day divided into 3 doses daily; doses up to 2,400 mg/day divided into 3 doses daily are well tolerated long-term; maximum daily dose: Doses up to 3,600 mg/<b>day</b> have been tolerated in short-term studies.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="393e56f7-bded-45b3-b486-3009d2e7543b">Neuropathic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain:</b> Limited data available: Children and Adolescents: Immediate release: Oral: Initial: 5 mg/kg/dose at bedtime, maximum dose: 300 mg/dose; day 2: Increase to 5 mg/kg/dose twice daily, maximum dose: 300 mg/dose; day 3: Increase to 5 mg/kg/dose 3 times daily, maximum dose: 300 mg/dose; further titrate with dosage increases (not frequency) to effect; usual dosage range: 8 to 35 mg/kg/<b>day</b> divided into 3 doses daily; maximum daily dose: 3,600 mg/<b>day</b>; do not exceed 12 hours between doses with 3-times-daily dosing; a lower initial dose may be considered if concurrent analgesics are also sedating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AmPainSociety.2008','lexi-content-ref-33147808','lexi-content-ref-10835999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AmPainSociety.2008','lexi-content-ref-33147808','lexi-content-ref-10835999'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110605"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years: There are no dosing adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: See table.</p>
<table border="1" data-table-id="gabador" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:center;">
<b>Gabapentin Dosing Adjustments in Renal Impairment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Total Daily Dose Range</p></th>
<th align="center" colspan="5" valign="middle">
<p style="text-indent:0em;">Dosage Regimens</p>
<p style="text-indent:0em;">(Maintenance Doses)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="7">
<p style="text-indent:0em;">
<sup>a </sup>CrCl &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance.</p></td></tr>
<tr>
<td align="left" colspan="7">
<p style="text-indent:0em;">
<sup>b </sup>Supplemental dose should be administered after each 4 hours of hemodialysis (patients on hemodialysis should also receive maintenance doses based on renal function as listed in the upper portion of the table).</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">≥60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">900 to 3,600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">800 mg 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">1,200 mg 3 times daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;30 to 59 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">400 to 1,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">700 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;15 to 29 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">200 to 700 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">700 mg daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 mL/minute<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">100 to 300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">125 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg daily</p></td></tr>
<tr>
<td align="center" colspan="2" rowspan="2" valign="middle">
<p style="text-indent:0em;">
<b>Hemodialysis<sup>b</sup></b></p></td>
<td align="center" colspan="5">
<p style="text-indent:0em;">
<b>Posthemodialysis Supplemental Dose</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">125 mg</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg</p></td>
<td align="center">
<p style="text-indent:0em;">350 mg</p></td></tr></tbody></table></div>
<div class="block dohp drugH1Div" id="F51110606"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment not necessary since gabapentin is not hepatically metabolized.</p></div>
<div class="block arsc drugH1Div" id="F54371955"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS and respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gabapentin may cause dose-dependent CNS depression and present as <b>dizziness </b>and/or <b>drowsiness</b>. In addition, serious, life-threatening, and fatal <b>respiratory depression</b> may occur; most cases occur with concomitant use of CNS depressants (especially opioids) in the setting of underlying respiratory impairment or in older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>). CNS depression may impair physical or mental abilities and result in <b>accidental injury, </b>including falls.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action (ie, structurally related to GABA)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; timing impacted by concomitant use of medications known to cause CNS depression (eg, opioids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of alcohol or other CNS depressants (eg, opioids, benzodiazepines, antidepressants, antihistamines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019','lexi-content-ref-36777316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019','lexi-content-ref-36777316'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Patients with underlying respiratory impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis </b>or <b>angioedema </b>may occur<b>. </b>Signs and symptoms may include <b>dyspnea</b>, swelling of the lips, throat, and tongue, and <b>hypotension </b>(manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; immunologic. In general, anaphylaxis is an IgE-mediated reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32001253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32001253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; most anaphylactic reactions occur within minutes to hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28611774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28611774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior history of immediate hypersensitivity reaction to gabapentin. <b>Note: </b>It is unknown whether cross-reactivity exists between gabapentin and pregabalin, given their similar structures. If an agent with similar structure is prescribed in a patient with a documented allergy to this drug, the possibility of cross-reactivity should be considered.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isolated cases of dermatologic reactions, including maculopapular skin rash<b>, </b>
<b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS), <b>Stevens-Johnson syndrome</b>, <b>toxic epidermal necrolysis,</b>
<b>bullous pemphigoid</b>, <b>erythema multiforme</b>, and <b>hypersensitivity angiitis</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10051068','lexi-content-ref-30326409','lexi-content-ref-28241331','lexi-content-ref-18097126','lexi-content-ref-29027197','lexi-content-ref-9831433','lexi-content-ref-37799214','lexi-content-ref-16616830','lexi-content-ref-11307046','lexi-content-ref-18382181','lexi-content-ref-33130590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10051068','lexi-content-ref-30326409','lexi-content-ref-28241331','lexi-content-ref-18097126','lexi-content-ref-29027197','lexi-content-ref-9831433','lexi-content-ref-37799214','lexi-content-ref-16616830','lexi-content-ref-11307046','lexi-content-ref-18382181','lexi-content-ref-33130590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; immunologic; Delayed hypersensitivity reactions are mediated by T-cells or antibodies other than IgE (eg, IgG-mediated, such as some cytopenias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Severe cutaneous adverse reactions (SCARs) are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; type IV reactions are delayed hypersensitivity reactions that typically occur days to weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of delayed hypersensitivity reaction to gabapentin. <b>Note: </b>It is unknown whether cross-reactivity exists between gabapentin and pregabalin, given their similar structures. If an agent with similar structure is prescribed in a patient with a documented allergy to this drug, the possibility of cross-reactivity should be considered. Gabapentin is usually considered a safe agent for patients with a previous history of drug allergies to other antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10199060','lexi-content-ref-11307046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10199060','lexi-content-ref-11307046'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neuropsychiatric adverse reactions have occurred in pediatric patients (ages 3 to 12 years) with epilepsy, including <b>emotional lability</b>; <b>hostility</b> (eg, aggressive behaviors); changes in behavior and thinking (eg, concentration problems, changes in school performance); and <b>hyperkinetic muscle activity</b> (eg, restlessness, hyperactivity). In addition, <b>agitation</b> has been reported following use for neuropathic pain in adult patients with cognitive impairment secondary to brain injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9210989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9210989'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; exact mechanism not established; one theory is gabapentin results in disinhibition similar to what is seen following benzodiazepine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8603631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8603631'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Children with intellectual disabilities and attention-deficit/hyperactivity disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8603631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8603631'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation and tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications (ASMs) have been associated with <b>suicidal ideation</b> and <b>suicidal tendencies</b>. However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some ASMs (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as postictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). In one retrospective cohort study, gabapentinoids were associated with an increased risk for suicidal behavior and pregabalin was associated with a higher risk as compared to gabapentin; however, the impact of confounding variables (eg, alcohol use, illicit drug use) could not be fully elucidated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related. Exact mechanism not established; one theory is antiseizure medications lower the threshold for manifesting psychiatric symptoms in patients susceptible to psychiatric disorders or antiseizure-induced disinhibition and impulsiveness, thereby influencing and promoting suicidal acts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30488008','lexi-content-ref-21479999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30488008','lexi-content-ref-21479999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254','lexi-content-ref-20388896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254','lexi-content-ref-20388896'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for suicidal thoughts and behaviors (including epilepsy)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of psychiatric disorders or aggressive behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30488008','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30488008','lexi-content-ref-22994856'])">Ref</a></span>), including history of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use in conditions other than epilepsy (eg, chronic pain conditions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37538401','lexi-content-ref-20818889','lexi-content-ref-32438065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37538401','lexi-content-ref-20818889','lexi-content-ref-32438065'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F174988"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. [IR = Immediate Release, ER = Extended Release]</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (IR, children: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (IR, adolescents and adults: 1% to 13%), dizziness (IR, adolescents and adults: 17% to 28%; ER, adults: 11%; IR, children: 3%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Dizziness</span>, drowsiness (IR, adolescents and adults: 19% to 21%; IR, children: 8%; ER, adults: 5%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Drowsiness</span>, fatigue (IR, adolescents and adults: 11%; IR, children: 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Dizziness" frame="border" id="lexi-content-gabapentin-adverse-reaction-dizziness" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">119</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">543</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">336</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Drowsiness" frame="border" id="lexi-content-gabapentin-adverse-reaction-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">119</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">543</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">336</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (ER, adults: &gt;1%), peripheral edema (adolescents and adults: 2% to 8%), vasodilation (IR, adolescents and adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (IR, adolescents and adults: 1%), skin rash (ER, adults: &gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (IR, adults: 1%), weight gain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (adolescents and adults: 1% to 4%), dental disease (IR, adolescents and adults: 2%), diarrhea (IR, adults: 6%), dyspepsia (adolescents and adults: 1% to 2%), nausea (IR: ≤8%; ER, adults: &gt;1%), viral gastroenteritis (ER, adults: &gt;1%), vomiting (IR: ≤8%), xerostomia (adolescents and adults: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (IR, adolescents and adults: 2%), urinary tract infection (ER, adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (ER, adults: &gt;1%), infection (IR, adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (IR, adults: 2%), amnesia (IR, adolescents and adults: 2%), asthenia (IR, adults: 6%), changes in thinking (IR, adolescents and adults: 2% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Changes in Thinking table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-changes-in-thinking" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-changes-in-thinking')">table 3</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Changes in Thinking</span>, confusion (ER, adults: &gt;1%), depression (IR, adolescents and adults: 2%), dysarthria (IR, adolescents and adults: 2%), emotional lability (IR, children: 4% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Emotional Lability table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-emotional-lability" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-emotional-lability')">table 4</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Emotional Lability</span>, hostility (IR, children: 5% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Hostility table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-hostility" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-hostility')">table 5</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Hostility</span>, lethargy (ER, adults: 1%), memory impairment (ER, adults: &gt;1%), pain (ER, adults: 1%), status epilepticus (IR, adolescents and adults: 2%), tremor (IR, adolescents and adults: 7%), vertigo (ER, adults: 1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Changes in Thinking" frame="border" id="lexi-content-gabapentin-adverse-reaction-changes-in-thinking" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Changes in Thinking</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">543</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">336</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">227</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Emotional Lability" frame="border" id="lexi-content-gabapentin-adverse-reaction-emotional-lability" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Emotional Lability</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">119</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Hostility" frame="border" id="lexi-content-gabapentin-adverse-reaction-hostility" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Hostility</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">119</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (adolescents and adults: 2%), hyperkinetic muscle activity (IR, children: 3% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Hyperkinetic Muscle Activity table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-hyperkinetic-muscle-activity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-hyperkinetic-muscle-activity')">table 6</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Hyperkinetic Muscle Activity</span>, joint swelling (ER, adults: &gt;1%), limb pain (ER, adults: 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Hyperkinetic Muscle Activity" frame="border" id="lexi-content-gabapentin-adverse-reaction-hyperkinetic-muscle-activity" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Hyperkinetic Muscle Activity</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Epilepsy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">119</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (IR: 3% to 4%), conjunctivitis (IR, adults: 1%), diplopia (IR, adolescents and adults: 1% to 6%), nystagmus disorder (IR, adolescents and adults: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (IR, adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (IR, children: 3%), cough (IR, adolescents and adults: 2%), dry throat (IR, adolescents and adults: ≤2%), nasopharyngitis (ER, adults: 3%), pharyngitis (IR, adolescents and adults: 1% to 3%), pneumonia (ER, adults: &gt;1%), respiratory tract infection (IR, children: 3%), upper respiratory tract infection (ER, adults: &gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (IR, adults: 3%)<span class="lexi-table-link-container"> (<a aria-label="Gabapentin: Adverse Reaction: Accidental Injury table link" class="lexi-table-link" data-table-id="lexi-content-gabapentin-adverse-reaction-accidental-injury" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gabapentin-adverse-reaction-accidental-injury')">table 7</a>)</span><span class="table-link" style="display:none;">Gabapentin: Adverse Reaction: Accidental Injury</span>, fever (IR, children: 10%; ER, adults: &gt;1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gabapentin: Adverse Reaction: Accidental Injury" frame="border" id="lexi-content-gabapentin-adverse-reaction-accidental-injury" rules="all">
<caption style="text-align:center;">
<b>Gabapentin: Adverse Reaction: Accidental Injury</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Gabapentin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">336</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">227</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (Tellor 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Flamm 2017), dermatitis (interstitial granulomatous) (Georgesen 2014), erythema multiforme, Stevens-Johnson syndrome (De Toledo 1999; Frey 2017; Sudana 2020), toxic epidermal necrolysis (Oskay 2006; Ragucci 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered serum glucose, amenorrhea (Berger 2004), change in libido, hypoglycemia (Penumalee 2003; Scholl 2015), hyponatremia (Falhammar 2018; Lu 2017; Wilton 2002), thyroiditis (Fyre 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (Labbate 1999), breast hypertrophy (Zylicz 2000), ejaculation failure (Labbate 1999), ejaculatory disorder, urinary incontinence (Rissardo 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Ataki 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Jackson 2018), increased liver enzymes (Jackson 2018; Lasso-de-la-Vega 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Chong 2021), drug reaction with eosinophilia and systemic symptoms (Ragucci 2001; Scaparotta 2011), hypersensitivity angiitis (Sahin 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Parasitic infection (Lopez 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Childers 1997), coma (Abdennour 2017; Butler 2003; Dogukan 2006), encephalopathy (Beauvais 2015), movement disorder (Allford 2007; Attupurath 2009; Palomeras 2000; Pina 2005; Raju 2007; Rissardo 2023; Rohman 2014; Souzdalnitski 2014; Twardowschy 2008; Zesiewicz 2008), myoclonus (facial) (Hampton 2019; Hui 2019; Yeddi 2019), polyneuropathy (Gould 1998), stuttering (Nissani 1997), suicidal ideation (Molero 2019), suicidal tendencies (Molero 2019), visual hallucination (Parsons 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen, rhabdomyolysis (Bilgir 2009; Choi 2017; Coupal 2017; Lipson 2005; Tuccori 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression (FDA 2019)</p></div>
<div class="block coi drugH1Div" id="F175005"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gabapentin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F174985"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: The safety and efficacy of the ER formulation has not been studied in patients with epilepsy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance abuse: Use with caution in patients with a history of substance abuse, including alcohol, benzodiazepines, cannabis, cocaine, and opioids; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur (Evoy 2017; Mersfelder 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: IR and ER products are not interchangeable with each other or with gabapentin enacarbil due to differences in formulations, indications, and pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumorigenic potential: Male rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication in humans is unknown).</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency in patients with epilepsy or other withdrawal symptoms (eg, confusion, irritability, tachycardia, diaphoresis). Therapy should be withdrawn gradually over ≥1 week to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal (Norton 2001; Tran 2005).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57180402"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Withdrawal has been described following abrupt discontinuation of gabapentin in infants; reported symptoms included episodic tachycardia, emesis, and irritability; symptoms resolved after gabapentin was restarted. Avoid abrupt discontinuation, especially in patients on prolonged therapy (use &gt;1 week); it has been recommended that gabapentin be continued even if patients are made nothing by mouth (NPO) (Carrasco 2015; Edwards 2016; McPherson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia has been reported in infants receiving gabapentin. A case series reported bradycardia occurred within 24 hours of initiation of gabapentin in former 26-week GA twins; the dose was lowered with resolution of bradycardia in one twin; the other twin had gabapentin discontinued without a trial of a lower dose (Edwards 2016). Another case series reported bradycardia in 3 infants; however, all infants were also receiving other medications known to increase risk of bradycardia; following a reduction in the gabapentin dose, bradycardia resolved (O'Mara 2018). Patients should be monitored closely.</p></div>
<div class="block foc drugH1Div" id="F174997"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neurontin: 100 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neurontin: 250 mg/5 mL (470 mL) [strawberry anise flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (473 mL); 250 mg/5 mL (5 mL, 6 mL, 470 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gralise: 450 mg, 750 mg, 900 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neurontin: 600 mg, 800 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg, 800 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, Extended Release: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gralise: 300 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gralise: 600 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg, 600 mg</p></div>
<div class="block geq drugH1Div" id="F174981"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F175007"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Gabapentin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.11 - $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.15 - $2.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.03 - $1.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Neurontin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $8.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $9.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Misc</b> (Gralise Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 (9) &amp;600(24) MG (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gabapentin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.32 - $0.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neurontin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $1.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Gabapentin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $0.07 - $2.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $0.11 - $3.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Gralise Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $12.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg (per each): $12.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $12.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $19.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg (per each): $19.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Neurontin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $15.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $18.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867009"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neurontin: 100 mg, 300 mg, 400 mg [contains corn starch, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neurontin: 600 mg, 800 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg, 800 mg</p></div>
<div class="block adm drugH1Div" id="F175001"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: May administer without regards to meals. Administer first dose on first day at bedtime to avoid somnolence and dizziness. Dosage must be adjusted for renal function; when given 3 times daily, the maximum time between doses should not exceed 12 hours. Capsules may be opened and sprinkled on food (eg, applesauce, orange juice, pudding) for patients unable to swallow capsules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9562133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9562133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Administer with evening meal. Swallow whole; do not chew, crush, or split.</p></div>
<div class="block admp drugH1Div" id="F52612898"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate release: Capsule, tablet, oral solution: May consider administration of first dose on first day at bedtime to avoid somnolence and dizziness. May be administered without regard to meals; administration with meals may decrease adverse GI effects. Dose may be administered as combination of dosage forms; do not administer within 2 hours of magnesium- or aluminum-containing antacids. When given 3 times daily, the maximum time between doses should not exceed 12 hours. Capsule should be administered with plenty of water to ensure complete swallowing. Although the manufacturer recommends swallowing capsules whole, some centers have opened the capsules and mixed the contents in drinks (eg, orange juice) or food (eg, applesauce) when necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9562133','lexi-content-ref-8648543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9562133','lexi-content-ref-8648543'])">Ref</a></span>). The 600 mg and 800 mg tablets are scored and may be split if a half-tablet is needed; manufacturer recommends that half tablets not used within 28 days of breaking the scored tablets should be discarded.</p></div>
<div class="block meg drugH1Div" id="F10916634"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Neurontin: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F020235s069%2C020882s050%2C021129s050lbl.pdf%23Page%3D28&amp;token=RTQVSKok6KRD37%2FXu3PZ2biCNiaK7WsIMZ4cZ43QBtksW5jczj3BLtdfpljcPQ7SgkYFy7v7k7etrMVEmxjlXtgwtK5TR9hlfXNKA9uiHwXOzToLZIz80S2rDnx97SIfgZfGZlcswnNnKuGb%2BtYxXw%3D%3D&amp;TOPIC_ID=8483" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020235s069,020882s050,021129s050lbl.pdf#Page=28</a></p>
<p style="text-indent:-2em;margin-left:4em;">Gralise: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022544s029lbl.pdf%23page%3D21&amp;token=JG9Z7pM9nQwjewUg2qo0%2B0HLzwzQ3oxHPmXpePsOQKgmJKe6BBHiSXSBZzyduDDb1V49WOqcZxSwoVnJuqOyPx7OsompCTbuaPIT88%2B6ckYPdXtPtowQmlyp4EUJm5Pe&amp;TOPIC_ID=8483" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022544s029lbl.pdf#page=21</a></p></div>
<div class="block use drugH1Div" id="F175000"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia:</b> Management of postherpetic neuralgia (PHN) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, focal (partial) onset (immediate release only):</b> As adjunctive therapy in the treatment of focal (partial) seizures with and without secondary generalization in adults and pediatric patients 3 years of age and older with epilepsy.</p></div>
<div class="block off-label drugH1Div" id="F25726013"><span class="drugH1">Use: Off-Label: Adult</span><p>Alcohol use disorder, moderate to severe (alternative agent); Alcohol withdrawal; Cough, chronic refractory; Generalized anxiety disorder; Fibromyalgia (alternative agent); Hiccups (singultus); Neuropathic pain (other than postherpetic neuralgia); Pruritus, chronic (neuropathic or malignancy related) (alternative agent); Pruritus, uremic; Restless legs syndrome; Social anxiety disorder, adjunct to antidepressants or monotherapy (alternative agent); Vasomotor symptoms associated with menopause</p></div>
<div class="block mst drugH1Div" id="F175068"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gabapentin may be confused with gabapentin enacarbil, gemfibrozil</p>
<p style="text-indent:-2em;margin-left:4em;">Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC], Zarontin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used for neuropathic pain) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299373"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F174990"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after administration of antacids containing aluminum hydroxide or magnesium hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cetirizine (Systemic): May enhance the CNS depressant effect of Gabapentin. Cetirizine (Systemic) may decrease the serum concentration of Gabapentin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May enhance the CNS depressant effect of Gabapentin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F175018"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Tablet, solution (immediate release): No significant effect on rate or extent of absorption; extended release tablet: Increases rate and extent of absorption. Management: Administer immediate release products without regard to food. Administer extended release with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F54124609"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use. Pregnancy testing is recommended before treating acute alcohol withdrawal symptoms (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Folic acid supplementation is recommended prior to becoming pregnant during gabapentin therapy (Borgelt 2016; Picchietti 2015).</p></div>
<div class="block pri drugH1Div" id="F175008"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gabapentin crosses the placenta (Ohman 2005; Ohman 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of gabapentin during pregnancy are available (Blotière 2019; Blotière 2020; Hernández-Díaz 2012; Holmes 2012; Mostacci 2018; Patorno 2020; Westin 2016). Folic acid supplementation is recommended during pregnancy in patients using gabapentin (Borgelt 2016; Picchietti 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Adequate data are not available to determine if pregnancy-induced physiologic changes alter gabapentin pharmacokinetic properties in a clinically significant way (Arfman 2020; Tomson 2019). Consider measuring the total gabapentin serum trough concentrations prior to conception during a period of stable seizure control and repeat during pregnancy and postpartum if dosage adjustments are needed to maintain seizure control (Arfman 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Gabapentin is used off-label for the treatment of restless leg syndrome; however, current guidelines note there is insufficient evidence to recommend its use in pregnant patients for this indication (Picchietti 2015). Pharmacological agents should not be used for the treatment of alcohol use disorder during pregnancy unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than gabapentin may be preferred when treatment is needed (APA [Reus 2018]; ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to gabapentin is ongoing. Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F175009"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of in gabapentin in breast milk are limited (Tomson 2022):</p>
<p style="text-indent:-2em;margin-left:4em;">• Data are available from 5 mother infant pairs, 14 to 97 days postpartum. In all cases, maternal use of gabapentin occurred during pregnancy and continued after delivery (dosage range 600 to 2100 mg/day). Breast milk samples were obtained prior to the morning dose and concentrations ranged from 7 to 51 µM (1.2 to 8.7 mcg/mL). After nursing, gabapentin was present in the serum of 3 infants and below the limit of quantification in a fourth infant (&lt;4 µM; 0.7 mcg/mL); one infant was not breastfed. The authors of the study calculated the estimated daily infant dose of gabapentin via breast milk to be 0.2 to 1.3 mg/kg/day providing a relative infant dose (RID) of 1.3 to 3.8% compared to weight-adjusted maternal dose. Adverse events were not reported in the breastfed infants (Ohman 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Data are also available from a patient 1.6 months postpartum taking gabapentin 600 mg 3 times daily for 6 weeks. Breast milk was sampled at intervals over ~23 hours after the maternal dose. Using the average breast milk concentration of 5.7 mcg/mL, the authors of the study calculated the estimated daily infant dose of gabapentin via breast milk to be 0.86 mg/kg/day, providing a RID of 2.34% compared to weight-adjusted maternal dose. The infant was breastfed 6 to 7 times daily and provided supplementary feedings at night; his plasma concentration of gabapentin was 0.4 mg/L (Kristensen 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• The average gabapentin breast milk/maternal serum concentration ratios in these studies was 1.0 (Tomson 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Based on limited data, gabapentin is considered relatively compatible with breastfeeding; infants should be monitored for drowsiness, adequate weight gain, and developmental milestones (Davanzo 2013; Veiby 2015). Available guidelines state gabapentin may be considered for the treatment of refractory restless leg syndrome in persons who are breastfeeding (Picchietti 2015). Pharmacological agents should not be used for the treatment of alcohol use disorder in breastfeeding patients unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder (APA [Reus 2018]).</p></div>
<div class="block dic drugH1Div" id="F175010"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Extended release tablet should be taken with food.</p></div>
<div class="block mop drugH1Div" id="F174995"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic renal function, suicidality (eg, suicidal thoughts, depression, behavioral changes); mental alertness; symptoms of respiratory depression and sedation in patients with underlying respiratory disease (FDA 2019); signs and symptoms of hypersensitivity (eg. anaphylaxis/angioedema, or possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and/or eosinophilia).</p></div>
<div class="block pha drugH1Div" id="F174984"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gabapentin is structurally related to GABA. However, it does not bind to GABA<sub>A</sub> or GABA<sub>B</sub> receptors, and it does not appear to influence degradation or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception. These effects on restless leg syndrome are unknown.</p></div>
<div class="block phk drugH1Div" id="F175004"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Variable, from proximal small bowel by L-amino transport system; saturable process; dose-dependent</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 58 ± 6 L; CSF concentrations are ~20% of plasma concentrations</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;3%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Inversely proportional to dose due to saturable absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">900 mg/day: 60%</p>
<p style="text-indent:-2em;margin-left:6em;">1,200 mg/day: 47%</p>
<p style="text-indent:-2em;margin-left:6em;">2,400 mg/day: 34%</p>
<p style="text-indent:-2em;margin-left:6em;">3,600 mg/day: 33%</p>
<p style="text-indent:-2em;margin-left:6em;">4,800 mg/day: 27%</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Variable; increased with higher fat content meal</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 month to Children 12 years: 4.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults, normal: 5 to 7 hours; increased half-life with decreased renal function; anuric adult patients: 132 hours; adults during hemodialysis: 3.8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Immediate release: Infants 1 month to Children 12 years: 2 to 3 hours; Adults: 2 to 4 hours; Extended release: 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Proportional to renal function; urine (as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Apparent oral clearance is directly proportional to CrCl: Clearance in infants is highly variable; oral clearance (per kg) in children &lt;5 years of age is higher than in children ≥5 years of age</p></div>
<div class="block phksp drugH1Div" id="F51196078"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Adults: In CrCl &lt;30 mL/minute, half-life is approximately 52 hours (immediate release). In moderate and severe renal impairment, Cl was decreased to 3 and 1 L/hour, respectively, compared with 5 to 7 L/hour in nonrenal impairment patients (ER).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175011"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Conventin | Gabapentin fidia | Gabatrex | Nervz | Neurontin | Neuroplex | Nurona</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Arapentin | Axilep | Logistic | Neurontin | Ultraneural</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin 1A Pharma | Gabapentin accord | Gabapentin actavis | Gabapentin arcana | Gabapentin Genericon | Gabapentin hexal | Gabapentin pfizer | Gabapentin ranbaxy | Gabapentin ratiopharm | Gabapentin torrex pharma | Gabapentin viatris | Gabatal | Neurontin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Apx gabapentin | Dbl gabapentin | Gabahexal | Gabapentin an | Gabapentin apotex | Gabapentin aspen | Gabapentin Ga | Gabapentin gh | Gabapentin pfizer | Gabapentin sandoz | Gabaran | Gabatine | Gantin | Gapentin | Genrx gabapentin | Neurontin | Nupentin | Pendine | Pharmacor Gabapentin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Epipen | Gabamax | Gabapen | Gabastar | Gabon | Gaboton | Gpentin | Nepsy | Neuropen | Neurotin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin sandoz | Gabapentine Apotex | Gabapentine bexal | Gabapentine eg | Gabapentine merck-generics | Gabapentine Mylan | Gabapentine Sandoz | Neurontin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Gabaneurine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabaneural | Gordius | Neurontin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Empak | Gabaneurin | Gabapentina | Gabapentina aurobindo | Gabapentina cimed | Gamibetal | Gapem | Neurocontrol | Neurontin | Progresse</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gabantin | Gabapentin Mepha | Gabapentin pfizer | Gabapentin sandoz eco | Gabapentin Spirig | Gabapentin spirig hc | Gabapentin teva | Neurontin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Gabaneurine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dineurin | Gabata | Gabex | Gabictal | Neurontin | Normatol | Ritmenal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Die li | Neurontin | Pai ting</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Agna | Ciplapentin | Gabantex | Gabapentina | Gabapentina Normon | Gabata | Kaptin | Neroden | Neurogabin | Neurontin</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Nervodin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Gab | Gabagamma | Gabalept | Gabanox | Gabapentin aurobindo | Gabapentin teva | Gabator | Gordius | Grimodin | Neurontin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabalich | Gabaliquid geriasan | Gabapentin 1 A Pharma | Gabapentin AAA | Gabapentin actavis | Gabapentin al | Gabapentin Almus | Gabapentin Aristo | Gabapentin aurobindo | Gabapentin basics | Gabapentin beta | Gabapentin biomo | Gabapentin CT | Gabapentin Desitin | Gabapentin dura | Gabapentin Esparma | Gabapentin glenmark | Gabapentin heumann | Gabapentin hexal | Gabapentin holsten | Gabapentin hormosan | Gabapentin pfizer | Gabapentin Pharvita | Gabapentin ratiopharm | Gabapentin sandoz | Gabapentin stada | Gabapentin tillomed | Gabapentine ratiopharm | Gabax | Neurontin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Gabadoz | Gabapenstad | Gabapentin "PCD" | Gabapentin 1a Farma | Gabapentin 2k | Gabapentin durascan | Gabapentin orifarm | Gabapentin paranova | Gabapentin Pliva | Gabapentin unp | Gabaratio</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gabaneuron | Gabapen | Gabapentina | Gabilep | Gaboton | Neurontin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dineurin | Fassdol | Gabantin | Gabapent | Gabapentina | Gabapentina caplin | Gabictal | Gapridol | Neurontin | Ox pentin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin accord | Gabapentin actavis | Neurontin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adaptan | Aminogrand | Conventin | Enhantin | Epicopentin | Gabalepsy | Gabimash | Gaptin | Lepticure | Neuroglopentin | Neurontin | Octoconval | Ramsoom | Shalgaten | Stablentin | Vegapantin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gabamerck | Gabapentina | Gabapentina Almus | Gabapentina Alter | Gabapentina Aphar | Gabapentina Apotex | Gabapentina aurobindo | Gabapentina aurovitas | Gabapentina bexal | Gabapentina cinfa | Gabapentina combino pharm | Gabapentina Combix | Gabapentina Curaxys | Gabapentina Kern | Gabapentina Korhispana | Gabapentina Normon | Gabapentina pharmacia | Gabapentina pharmagenus | Gabapentina Qualigen | Gabapentina Ranbaxy | Gabapentina ratiopharm | Gabapentina rubio | Gabapentina Sandoz | Gabapentina Stada | Gabapentina Tarbis | Gabapentina Tecnigen | Gabapentina Teva | Gabapentina Tevagen | Gabapentina tillomed | Gabapentina ur | Gabapentina viso | Gabapentina Winthrop | Gabatur | Gabmylan | Neurontin | Oxaquin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Neuran | Nurona</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gabapentiini Ennapharma | Gabapentin accord | Gabapentin actavis | Gabapentin hexal | Gabapentin Mylan | Gabapentin Pliva | Gabapentin ratiopharm | Gabapentin sandoz | Gabrion | Geabatan | Neurontin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gabapentine Actavis | Gabapentine Alter | Gabapentine Arrow | Gabapentine Biogaran | Gabapentine cristers | Gabapentine eg | Gabapentine evolugen | Gabapentine g gam | Gabapentine pfizer | Gabapentine qualimed | Gabapentine Ranbaxy | Gabapentine ratiopharm | Gabapentine RPG | Gabapentine Sandoz | Gabapentine teva | Gabapentine Winthrop | Gabapentine zydus | Neurontin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin accord | Gabapentin Almus | Gabapentin brown &amp; burk | Gabapentin glenmark | Gabapentin Kent | Gabapentin Pliva | Gabapentin teva | Gabapentin thame | Gabapentin tillomed | Gabapentin Wockhardt | Neurontin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Belgabin | Gabantin | Gabapentin/Generics | Gabapentin/mylan | Gabapentin/Teva | Gabaront | Gabental | Gabiton | Neurontin | Neuros | Pentin | Peronten</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Gabapentin sandoz | Gabenil | Gapatin | Neuran | Neurontin | Pms gabapentin | Vultin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Katena | Neurontin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabaneural | Gabapentin aurobindo | Gabator | Gordius | Grimodin | Neuroba | Neurontin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alpentin | Epiven | Gabasant | Gabexal | Galepsi | Ganin | Nepatic | Neurogesic | Neurontin | Neurosantin | Opipentin | Repligen | Sipentin | Tineuron</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin aurobindo | Gabapentin gerard | Gabapentin teva | Gabin | Neurontin | Neurostil | Rangabax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin teva | Neurontin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acegaba | Baga | Cynaptin | Encentin | G pen | Gaba | Gabacap | Gabacent | Gabaklas | Gabalent | Gabalept | Gabantin | Gabapax | Gabapin | Gabata | Gabatal | Gabateo | Gabator | Gabawell | Gabimax | Gabin | Laregab | Mygaba | Nervibrain | Neupent AF | Neurontin | Neuropentin | Neuropin | Pentanerv | Progaba | Rejunate | Shinogab</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Gabasaf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aclonium | Gabanex | Gabapentin abc | Gabapentin allen | Gabapentin Almus | Gabapentin aurobindo | Gabapentin Awp | Gabapentin doc generici | Gabapentin eg | Gabapentin fidia | Gabapentin merck | Gabapentin molteni | Gabapentin ranbaxy | Gabapentin ratiopharm | Gabapentin sandoz | Gabapentin Sigma Tau | Gabexine | Keneil | Neurontin | Semerial | Yalipent</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Gabanet | Gabatrex | Neurontin | Neuroplex | Nurona</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gabapen</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ablept | Coventin | Gabadin | Gabantin | Gabata | Gabator | Gabix | Laregab | Neogab | Neuroba | Neurontin | Onegaba | Vultin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abapen | Alpigabapentin | Ausgaba | Auspentin | Barontin | Baropentin | Binex gabapentin | Boryung gabapentin | Cabapen | Citpentine | Ct gaba | Dong a gabapentin | E roba | G&amp;b | Gaba act | Gabain | Gabaking | Gabalap | Gabalep | Gabape | Gabapen | Gabapenda | Gabapenin | Gabapin | Gabapron | Gabarex | Gabaron | Gabaronin | Gabarontin | Gabastil | Gabastin | Gabatin | Gabatiron | Gabatwo | Gabentin | Gabetin | Gabistar | Ganapina | Gapent | Gapentin | Gatin | Hyundai gabapentin | Legopentin | Megapentin | Neopentin | Neugaba | Neuleptol | Neulos | Neurocover | Neurogaba | Neurogapen | Neuroin | Neuronin | Neurontec | Neurontin | Neuropentin | Neuros | Neverpentin | New-gaba | Newbatin | Newbentin | Newgapen | Newpentin | Newratin | Paindown | Pendown | Pengatin | Penmix gabapentin | Pharma gabapentin | Pharvis gabastan | Pms gabapentin | Samsung gabapentin | Seoul Gabapentin | Teva gabapenqual | Unipentin | Unirontin | Wirontin | Withupentin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin abc | Neurontin | Neuroplex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Gabamox | Gabanet | Gabatrex | Neurontin | Neuroplex | Pms gabapentin | Volar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabapentin accord | Gabapentin actiopharma | Gabapentin nycomed | Gabapentin sandoz | Gordius | Grimodin | Neurontin | Nurabax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Neurontin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabapentin actavis | Gabapentin aurobindo | Gabapentin nycomed | Gabapentin sanoswiss | Gordius | Neurontin | Nurabax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Gabamox | Neurontin | Nupentin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bapex | Blugat | Clozepaxel | Compulxine | Convuntin | Darbentin | Gabantin | Gabapentina | Gapridol | Garantex | Kentopir | Microleptin | Neogamibetal | Neurontin | Nopatic | Nyepzyl | Regalden | Timic | Torgaptil | Wermy</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Dyna gabapentin | Gabantin | Gabapin | Gabenil | Gaboton | Neuran | Neurontin | Nupentin | Onegaba | Vultin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ablept | Gabatrust</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gabapentine | Gabapentine 50 mg/ml focus | Gabapentine A | Gabapentine accord | Gabapentine Alpharma | Gabapentine amarox | Gabapentine Aurobindo | Gabapentine Katwijk | Gabapentine Mylan | Gabapentine Sandoz | Neurontin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Gabaliquid geriasan | Gabapentin accord | Gabapentin actavis | Gabapentin GEA | Gabapentin hexal | Gabapentin rosemont | Gabapentin stada | Gabapentin teva | Neurontin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Arrow Gabapentin | Neurontin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Danolex | Daper | Dineurin | Gabantin | Gabapentina | Gabapentina medrock | Gabapin | Gabictal | Gapetina | Neugab | Neurodrint | Neurontin | Neuropentin | Nevromed</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aforpen | Fitfree | Gab | Gaba | Gabalept | Gabalion | Gabamed | Gabapen | Gabapentin sandoz | Gabapex | Gabarance | Gabaron | Gabator | Gabavex | Gabix | Garbapia | Neurontin | Neurosig | Onegaba | Reinin | Zycha</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anatin | Apentin | Aropen | Bapen | Biogaba | Blugat | Branon | Ciligab | Entin | Fitfree | Gaba | Gabafix | Gabafold | Gabagood | Gabanor | Gabaplus | Gabatic | Gabatin | Gabavant | Gabin | Gabix | Gabotin | Gaboz | Gaby | Gagbamaf | Gaptin | Gateban | Gatin | Gepent | Glorex | Hi gab | Indiga | Lepen | Ligab | Lisgab | M gob | Maxigab | Neogab | Nervex | Neupentin | Neurotin | Pentigab | Pentin | Pentowan | Pulsar | Raypentin | Tripentin | Vaniqa | Welgab | Winurina</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Epigapent | Gabacol | Gabagamma | Gabapentin aurovitas | Gabapentin teva | Gabapentin Torrex | Gabatem | Gabax | Neuran | Neurontin | Symleptic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gralise | Neurontin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gabamox | Gabapentin vitoria | Gabapentina | Gabapentina Almus | Gabapentina aurobindo | Gabapentina Azevedos | Gabapentina cinfa | Gabapentina Generis | Gabapentina germed | Gabapentina pd | Gabapentina Ranbaxy | Gabapentina sasivan | Gabapentina vitoria | Gabapentina Wynn | Neurontin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Butironal | Dineurol | Gabadin | Pricistin | Tonadrin | Ultraneural</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gabanet | Gabatrex | Gabix | Neurontin | Neuroplex | Nurona</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabalept | Gabapentin aurobindo | Gabapentin stada | Gabapentina pfizer | Gabaran | Grimodin | Neurontin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Convalis | Egipentin | Eplyrontin | Gabagamma | Gapentek | Katena | Lepsitin | Neurontin | Tebantin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Conventin | Gabanet | Gabatrex | Gabin | Gapentin | Neurontin | Neuroplex | Nulex | Pms gabapentin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gabapentin 1a Farma | Gabapentin 2care4 | Gabapentin accord | Gabapentin actavis | Gabapentin alternova | Gabapentin aurobindo | Gabapentin Ebb | Gabapentin eql | Gabapentin hexal | Gabapentin Medartuum | Gabapentin Merck NM | Gabapentin nycomed | Gabapentin orifarm | Gabapentin orion | Gabapentin pfizer | Gabapentin ranbaxy | Gabapentin rivopharm | Gabapentin sandoz | Gabapentin stada | Gabapentin strides | Gabapentin teva | Nelakap | Neurontin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo gabapentin | Gabapentin sandoz | Neurontin | Nupentin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Edion | Gabagamma | Neurontin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gabagamma | Gabapentin actavis | Gabapentin glenmark | Gabapentin teva | Gabapentin vipharm | Gabatem | Gordius | Grimodin | Neurontin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Berlontin | Epleptin | G-pentin | Gabantin | Gabapentin pfizer | Gabapentin sandoz | Gabapentin teva | Gabarex | Gabtin | Gabutin | Gapentin | Nervin | Neugaba | Neupentin | Neurontin | Rontin | Vultin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Gaba | Gabentin | Gabinor | Gaborex | Neuralgin | Neurontin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">As Gabapen | Eveptin | Gabaset | Gabateva | Gabtin | Nepitin | Neruda | Neurontin | Patyca</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Carbatin | Gapatin | Gatine | Neurontin | Remaltin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Epigaba | Gabalept | Gabantin | Gatonin | Meditan | Neyralgin | Nuropentine | Tebantin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Conventin | Neogab | Neuroba | Onegaba</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dineurol | Gabapentina | Gabapentina Sandoz | Galtoben | Neurontin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Epigan | Gabamox | Gabantin | Gabapentina | Gabapentina Kern | Gabictal | Gaboton | Neurontin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Begaba | Gabahasan | Gabaneutril | Galeptic | Gapivell | Glogapen | Mirgy | Narcutin | Neupencap | Neurohadine | Neuroncure | Noraquick | Nuradre | Ovaba | Rapozil | Usaneuro | Usarpeti</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Epigab | Epleptin | Neurexal | Neurontin | Senpras</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Gabator</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19300601">
<a name="19300601"></a>Abdennour L, Sanchez-Peña P, Galanaud D, Navarro V, Weiss N, Puybasset L. Gabapentin-induced coma: A MR-spectrometry analysis. <i>Neuropsychiatr Dis Treat</i>. 2007;3(5):695‐702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19300601/pubmed" id="19300601" target="_blank">19300601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31461226">
<a name="31461226"></a>Ahmed S, Stanciu CN, Kotapati PV, et al. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. <i>Prim Care Companion CNS Disord</i>. 2019;21(4):19r02465. doi:10.4088/PCC.19r02465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31461226/pubmed" id="31461226" target="_blank">31461226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17513320">
<a name="17513320"></a>Allford MA. Prolonged myotonia and dystonia after general anaesthesia in a patient taking gabapentin. <i>Br J Anaesth</i>. 2007;99(2):218‐220. doi:10.1093/bja/aem130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17513320/pubmed" id="17513320" target="_blank">17513320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17545753">
<a name="17545753"></a>Alonso-Navarro H, Rubio L, Jiménez-Jiménez FJ. Refractory hiccup: successful treatment with gabapentin. <i>Clin Neuropharmacol</i>. 2007;30(3):186-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17545753/pubmed" id="17545753" target="_blank">17545753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37538401">
<a name="37538401"></a>Alothman D, Tyrrell E, Lewis S, Card T, Fogarty AW. Evaluation of common prescription analgesics and adjuvant analgesics as markers of suicide risk: a longitudinal population-based study in England. <i>Lancet Reg Health Eur</i>. 2023;32:100695. doi:10.1016/j.lanepe.2023.100695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/37538401/pubmed" id="37538401" target="_blank">37538401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24463691">
<a name="24463691"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms [published correction appears in <i>Obstet Gynecol</i>. 2016;127(1):166]. <i>Obstet Gynecol</i>. 2014;123(1):202-216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24463691/pubmed" id="24463691" target="_blank">24463691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964887">
<a name="34964887"></a>American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: Standards of Medical Care in Diabetes-2022. <i>Diabetes Care</i>. 2022;45(suppl 1):S185-S194. doi:10.2337/dc22-S012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/34964887/pubmed" id="34964887" target="_blank">34964887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmPainSociety.2008">
<a name="AmPainSociety.2008"></a>American Pain Society.<i> Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. American Pain Society; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511109">
<a name="32511109"></a>American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. <i>J Addict Med</i>. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/32511109/pubmed" id="32511109" target="_blank">32511109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9099467">
<a name="9099467"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9099467/pubmed" id="9099467" target="_blank">9099467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7841578">
<a name="7841578"></a>Andrews CO, Fischer JH. Gabapentin: A new agent for the management of epilepsy. <i>Ann Pharmacother.</i> 1994;28(10):1188-96. doi: 10.1177/106002809402801011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7841578/pubmed" id="7841578" target="_blank">7841578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31247634">
<a name="31247634"></a>Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. <i>Curr Opin Allergy Clin Immunol</i>. 2019;19(4):283‐293. doi:10.1097/ACI.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31247634/pubmed" id="31247634" target="_blank">31247634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31912315">
<a name="31912315"></a>Arfman IJ, Wammes-van der Heijden EA, Ter Horst PGJ, et al. Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy. <i>Clin Pharmacokinet</i>. 2020;59(4):427-445. doi:10.1007/s40262-019-00845-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31912315/pubmed" id="31912315" target="_blank">31912315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17393438">
<a name="17393438"></a>Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. <i>Arthritis Rheum</i>. 2007;56(4):1336-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17393438/pubmed" id="17393438" target="_blank">17393438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26380421">
<a name="26380421"></a>Atakli D, Yuksel B, Ak PD, Sariahmetoglu H, Sari H. Thrombocytopenia with gabapentin usage. <i>Ideggyogy Sz</i>. 2015;68(7-8):270‐272. doi:10.18071/isz.68.0270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26380421/pubmed" id="26380421" target="_blank">26380421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23572323">
<a name="23572323"></a>Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. <i>Clin Drug Investig</i>. 2013;33(6):401-408. doi:10.1007/s40261-013-0080-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23572323/pubmed" id="23572323" target="_blank">23572323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20402746">
<a name="20402746"></a>Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <i>Eur J Neurol</i>. 2010;17(9):1113-1123, e67-e88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20402746/pubmed" id="20402746" target="_blank">20402746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19766954">
<a name="19766954"></a>Attupurath R, Aziz R, Wollman D, Muralee S, Tampi RR. Chorea associated with gabapentin use in an elderly man. <i>Am J Geriatr Pharmacother</i>. 2009;7(4):220‐224. doi:10.1016/j.amjopharm.2009.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19766954/pubmed" id="19766954" target="_blank">19766954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. <i>Sleep</i>. 2012;35(8):1039-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9846777">
<a name="9846777"></a>Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. <i>JAMA</i>. 1998;280(21):1831-1836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9846777/pubmed" id="9846777" target="_blank">9846777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32438065">
<a name="32438065"></a>Bailly F, Belaid H. Suicidal ideation and suicide attempt associated with antidepressant and antiepileptic drugs: implications for treatment of chronic pain. <i>Joint Bone Spine</i>. 2021;88(1):105005. doi:10.1016/j.jbspin.2020.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/32438065/pubmed" id="32438065" target="_blank">32438065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser G, Puntillo K, et al, “Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,” <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25200461">
<a name="25200461"></a>Beauvais K, Disson-Dautriche A, Jacquin A, Antoniol C, Martin ML. Gabapentin-induced encephalopathy. <i>Clin Neurophysiol</i>. 2015;126(4):845‐846. doi:10.1016/j.clinph.2014.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25200461/pubmed" id="25200461" target="_blank">25200461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk?. <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973‐992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30860637">
<a name="30860637"></a>Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. <i>Eur J Neurol</i>. 2019;26(6):831-849. doi:10.1111/ene.13950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30860637/pubmed" id="30860637" target="_blank">30860637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15100596">
<a name="15100596"></a>Berger JJ. Amenorrhea in a patient after treatment with gabapentin for complex regional pain syndrome type II. <i>Clin J Pain</i>. 2004;20(3):192‐194. doi:10.1097/00002508-200405000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15100596/pubmed" id="15100596" target="_blank">15100596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19525604">
<a name="19525604"></a>Bilgir O, Calan M, Bilgir F, et al. Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. <i>Intern Med</i>. 2009;48(12):1085‐1087. doi:10.2169/internalmedicine.48.1766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19525604/pubmed" id="19525604" target="_blank">19525604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32513880">
<a name="32513880"></a>Blotière PO, Miranda S, Weill A, et al. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. <i>BMJ Open</i>. 2020;10(6):e034829. doi:10.1136/bmjopen-2019-034829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/32513880/pubmed" id="32513880" target="_blank">32513880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189695">
<a name="31189695"></a>Blotière PO, Raguideau F, Weill A, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. <i>Neurology</i>. 2019;93(2):e167-e180. doi:10.1212/WNL.0000000000007696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31189695/pubmed" id="31189695" target="_blank">31189695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8062491">
<a name="8062491"></a>Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. <i>Clin Pharmacol Ther</i>. 1994;56(2):154-159. doi:10.1038/clpt.1994.118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8062491/pubmed" id="8062491" target="_blank">8062491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183‐198. doi:10.1016/S0140-6736(18)32218-32219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12373695">
<a name="12373695"></a>Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. <i>Reg Anesth Pain Med</i>. 2002;27(5):481-486. doi:10.1053/rapm.2002.35169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12373695/pubmed" id="12373695" target="_blank">12373695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20019070">
<a name="20019070"></a>Bonnet U, Hamzavi-Abedi R, Specka M, et al. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. <i>Alcohol Alcohol</i>. 2010;45(2):143-145. doi:10.1093/alcalc/agp085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20019070/pubmed" id="20019070" target="_blank">20019070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27703396">
<a name="27703396"></a>Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. <i>Int J Womens Health</i>. 2016;8:505-517. doi:10.2147/IJWH.S98973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27703396/pubmed" id="27703396" target="_blank">27703396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482920">
<a name="21482920"></a>Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in <i>Neurology</i>. 2011;77(6):603]. <i>Neurology</i>. 2011;76(20):1758-1765. doi: 10.1212/WNL.0b013e3182166ebe<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/21482920/pubmed" id="21482920" target="_blank">21482920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94‐105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18540923">
<a name="18540923"></a>Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. <i>Alcohol Clin Exp Res</i>. 2008;32(8):1429-1438. doi:10.1111/j.1530-0277.2008.00706.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18540923/pubmed" id="18540923" target="_blank">18540923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10642063">
<a name="10642063"></a>Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. <i>J Eur Acad Dermatol Venereol</i>. 1999;13(3):227-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10642063/pubmed" id="10642063" target="_blank">10642063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31343730">
<a name="31343730"></a>Burnsed JC, Heinan K, Letzkus L, Zanelli S. Gabapentin for pain, movement disorders, and irritability in neonates and infants. <i>Dev Med Child Neurol</i>. 2020;62(3):386-389. doi:10.1111/dmcn.14324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31343730/pubmed" id="31343730" target="_blank">31343730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12503937">
<a name="12503937"></a>Butler TC, Rosen RM, Wallace AL, Amsden GW. Flumazenil and dialysis for gabapentin-induced coma. <i>Ann Pharmacother</i>. 2003;37(1):74‐76. doi:10.1345/aph.1C242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12503937/pubmed" id="12503937" target="_blank">12503937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26278632">
<a name="26278632"></a>Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. <i>Pediatr Neurol</i>. 2015;53(5):445-447. doi:10.1016/j.pediatrneurol.2015.06.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26278632/pubmed" id="26278632" target="_blank">26278632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26131874">
<a name="26131874"></a>Carvalho S, Sanches M, Alves R, Selores M. Brachioradial pruritus in a patient with cervical disc herniation and Parsonage-Turner syndrome. <i>An Bras Dermatol</i>. 2015;90(3):401-402. doi:10.1590/abd1806-4841.20153059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26131874/pubmed" id="26131874" target="_blank">26131874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27984223">
<a name="27984223"></a>Cavalcante AN, Sprung J, Schroeder DR, Weingarten TN. Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression. <i>Anesth Analg</i>. 2017;125(1):141‐146. doi:10.1213/ANE.0000000000001719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27984223/pubmed" id="27984223" target="_blank">27984223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25577930">
<a name="25577930"></a>Centre for Clinical Practice at NICE (UK). Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings [Internet]. London: National Institute for Health and Care Excellence, (UK); November 2013. <a href="http://www.ncbi.nlm.nih.gov/books/NBK266257" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK266257</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25577930/pubmed" id="25577930" target="_blank">25577930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9210989">
<a name="9210989"></a>Childers MK, Holland D. Psychomotor agitation following gabapentin use in brain injury. <i>Brain Inj</i>. 1997;11(7):537‐540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9210989/pubmed" id="9210989" target="_blank">9210989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27389284">
<a name="27389284"></a>Choi MS, Jeon H, Kim HS, et al. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. <i>Hemodial Int</i>. 2017;21(1):E4‐E8. doi:10.1111/hdi.12458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27389284/pubmed" id="27389284" target="_blank">27389284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34295638">
<a name="34295638"></a>Chong KC, Hsu TH. Gabapentin-induced angioedema of tongue. <i>J Acute Med</i>. 2021;11(2):72-73. doi:10.6705/j.jacme.202106_11(2).0005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/34295638/pubmed" id="34295638" target="_blank">34295638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause—2017 update [published correction appears in <i>Endocr Pract</i>. 2017;23(12):1488]. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28567183">
<a name="28567183"></a>Coupal TM, Chang DR, Pennycooke K, Ouellette HA, Munk PL. Radiologic findings in gabapentin-induced myositis. <i>J Radiol Case Rep</i>. 2017;11(4):30‐37. doi:10.3941/jrcr.v11i4.3092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28567183/pubmed" id="28567183" target="_blank">28567183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.2021">
<a name="Craske.2021"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23985170">
<a name="23985170"></a>Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. <i>Ital J Pediatr</i>. 2013;39:50. doi:10.1590/abd1806-4841.20153059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23985170/pubmed" id="23985170" target="_blank">23985170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30833302">
<a name="30833302"></a>Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. <i>Clin J Am Soc Nephrol</i>. 2019;14(6):917-931. doi:10.2215/CJN.05180418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30833302/pubmed" id="30833302" target="_blank">30833302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24517512">
<a name="24517512"></a>Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. <i>Semin Dial</i>. 2014;27(2):188-204. doi:10.1111/sdi.12196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24517512/pubmed" id="24517512" target="_blank">24517512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33147808">
<a name="33147808"></a>de Leeuw TG, der Zanden TV, Ravera S, et al. Diagnosis and treatment of chronic neuropathic and mixed pain in children and adolescents: results of a survey study amongst practitioners. <i>Children (Basel)</i>. 2020;7(11):208. doi:10.3390/children7110208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/33147808/pubmed" id="33147808" target="_blank">33147808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16908377">
<a name="16908377"></a>Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. <i>J Am Acad Dermatol.</i> 2006;55(3):543-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16908377/pubmed" id="16908377" target="_blank">16908377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10051068">
<a name="10051068"></a>DeToledo JC, Minagar A, Lowe MR, Ramsay RE. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson's syndrome. <i>Ther Drug Monit</i>. 1999;21(1):137‐138. doi:10.1097/00007691-199902000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10051068/pubmed" id="10051068" target="_blank">10051068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16623669">
<a name="16623669"></a>Dogukan A, Aygen B, Berilgen MS, Dag S, Bektas S, Gunal AI. Gabapentin-induced coma in a patient with renal failure. <i>Hemodial Int</i>. 2006;10(2):168‐169. doi:10.1111/j.1542-4758.2006.00089.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16623669/pubmed" id="16623669" target="_blank">16623669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24938318">
<a name="24938318"></a>Dolgun H, Turkoglu E, Kertmen H, et al. Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial. <i>Neurol Res</i>. 2014;36(12):1080-1085. doi:10.1179/1743132814Y.0000000404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24938318/pubmed" id="24938318" target="_blank">24938318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26578075">
<a name="26578075"></a>Edwards L, DeMeo S, Hornik CD, et al. Gabapentin use in the neonatal intensive care unit. <i>J Pediatr</i>. 2016;169:310-312. doi:10.1016/j.jpeds.2015.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26578075/pubmed" id="26578075" target="_blank">26578075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507636">
<a name="36507636"></a>ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S203-S215. doi:10.2337/dc23-S012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/36507636/pubmed" id="36507636" target="_blank">36507636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30326409">
<a name="30326409"></a>Ernst JJ, Ryba D. Gabapentin-induced eczematous drug eruption of the bilateral foot. <i>Foot (Edinb)</i>. 2018;37:45‐47. doi:10.1016/j.foot.2018.06.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30326409/pubmed" id="30326409" target="_blank">30326409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28144823">
<a name="28144823"></a>Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. <i>Drugs</i>. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28144823/pubmed" id="28144823" target="_blank">28144823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29730273">
<a name="29730273"></a>Falhammar H, Lindh JD, Calissendorff J, et al. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study. <i>Seizure</i>. 2018;59:28‐33. doi:10.1016/j.seizure.2018.04.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/29730273/pubmed" id="29730273" target="_blank">29730273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2019">
<a name="FDA.2019"></a>FDA Safety Alert. MedWatch. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). Food and Drug Administration website. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin</a>. Published December 19, 2019. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.2018">
<a name="Feldman.2018"></a>Feldman EL. Management of diabetic neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575710">
<a name="25575710"></a>Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurol</i>. 2015;14(2):162-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25575710/pubmed" id="25575710" target="_blank">25575710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28241331">
<a name="28241331"></a>Flamm A, Sachdev S, Dufresne F. Gabapentin-Induced Bullous Pemphigoid. <i>J Am Osteopath Assoc</i>. 2017;117(3):191‐193. doi:10.7556/jaoa.2017.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28241331/pubmed" id="28241331" target="_blank">28241331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18097126">
<a name="18097126"></a>Fletcher R, Butcher H, Raw J, Naqvi N. Gabapentin and hypersensitivity syndrome. <i>J Postgrad Med</i>. 2007;53(4):276‐277. doi:10.4103/0022-3859.37527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18097126/pubmed" id="18097126" target="_blank">18097126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29027197">
<a name="29027197"></a>Frey N, Bodmer M, Bircher A, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. <i>Epilepsia</i>. 2017;58(12):2178‐2185. doi:10.1111/epi.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/29027197/pubmed" id="29027197" target="_blank">29027197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9934948">
<a name="9934948"></a>Frye MA, Luckenbaugh D, Kimbrell TA, et al. Possible gabapentin-induced thyroiditis. <i>J Clin Psychopharmacol</i>. 1999;19(1):94‐95. doi:10.1097/00004714-199902000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9934948/pubmed" id="9934948" target="_blank">9934948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18052562">
<a name="18052562"></a>Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. <i>J Clin Psychiatry</i>. 2007;68(11):1691-1700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18052562/pubmed" id="18052562" target="_blank">18052562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10835999">
<a name="10835999"></a>Galloway KS, Yaster M. Pain and symptom control in terminally ill children. <i>Pediatr Clin North Am</i>. 2000;47(3):711-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10835999/pubmed" id="10835999" target="_blank">10835999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33424664">
<a name="33424664"></a>Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. <i>Front Psychiatry</i>. 2020;11:595584. doi:10.3389/fpsyt.2020.595584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/33424664/pubmed" id="33424664" target="_blank">33424664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12451200">
<a name="12451200"></a>Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. <i>Neurology</i>. 2002;59(10):1573-1579. doi:10.1212/wnl.59.10.1573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12451200/pubmed" id="12451200" target="_blank">12451200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22937989">
<a name="22937989"></a>Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22937989/pubmed" id="22937989" target="_blank">22937989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25384220">
<a name="25384220"></a>Georgesen C, McDonough P, Cruz P. Interstitial granulomatous dermatitis associated with gabapentin. <i>Dermatitis</i>. 2014;25(6):374‐375. doi:10.1097/DER.0000000000000080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25384220/pubmed" id="25384220" target="_blank">25384220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30488008">
<a name="30488008"></a>Ghaly RF, Plesca A, Rana S, Candido KD, Knezevic NN. Gabapentin-related suicide: Myth or fact?. <i>Surg Neurol Int</i>. 2018;9:210. doi:10.4103/sni.sni_420_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30488008/pubmed" id="30488008" target="_blank">30488008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26426314">
<a name="26426314"></a>Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel. Treatment of unexplained chronic cough: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(1):27-44. doi:10.1378/chest.15-1496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26426314/pubmed" id="26426314" target="_blank">26426314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562133">
<a name="9562133"></a>Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition.<i> Ann Pharmacother</i>. 1998;32(4):405-409. doi: 10.1345/aph.17281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9562133 /pubmed" id="9562133 " target="_blank">9562133 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2018">
<a name="Goldenberg.2018"></a>Goldenberg DL. Initial treatment of fibromyalgia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9831433">
<a name="9831433"></a>Gonzalez-Sicilia L, Cano A, Serrano M, Hernandez J. Stevens-Johnson syndrome associated with gabapentin. <i>Am J Med</i>. 1998;105(5):455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9831433/pubmed" id="9831433" target="_blank">9831433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9520250">
<a name="9520250"></a>Gould HJ. Gabapentin induced polyneuropathy. <i>Pain</i>. 1998;74(2-3):341‐343. doi:10.1016/s0304-3959(97)00188-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9520250/pubmed" id="9520250" target="_blank">9520250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gralise.2020.04">
<a name="Gralise.2020.04"></a>Gralise (gabapentin) [prescribing information]. Newark, CA: Depomed, Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22279347">
<a name="22279347"></a>Guddati AK, Zafar Z, Cheng JT, Mohan S. Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy. <i>Indian J Nephrol</i>. 2012;22(1):59-61. doi: 10.4103/0971-4065.83744.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22279347/pubmed" id="22279347" target="_blank">22279347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15575002">
<a name="15575002"></a>Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. <i>Nephrol Dial Transplant</i>. 2004;19(12):3137-3139. doi:10.1093/ndt/gfh496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15575002/pubmed" id="15575002" target="_blank">15575002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10199060">
<a name="10199060"></a>Hamer HM, Morris HH. Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants. <i>Cleve Clin J Med</i>. 1999;66(4):239‐245. doi:10.3949/ccjm.66.4.239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10199060/pubmed" id="10199060" target="_blank">10199060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31363439">
<a name="31363439"></a>Hampton Z, Shahrestani N, Little A. Gabapentin-induced facial myoclonus in the setting of acute on chronic kidney disease. <i>Cureus</i>. 2019;11(5):e4758. doi:10.7759/cureus.4758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31363439/pubmed" id="31363439" target="_blank">31363439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14504416">
<a name="14504416"></a>Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. <i>Neuropsychobiology.</i> 2003;48(2):82-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14504416/pubmed" id="14504416" target="_blank">14504416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23585393">
<a name="23585393"></a>Helldén A, Odar-Cederlöf I, Nilsson G, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. <i>BMJ Open</i>. 2013;3(4):pii: e002686. doi:10.1136/bmjopen-2013-002686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23585393/pubmed" id="23585393" target="_blank">23585393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15308440">
<a name="15308440"></a>Hernandez JL, Pajarón M, García-Regata O, Jiménez V, González-Macías J, Ramos-Estébanez C. Gabapentin for intractable hiccup. <i>Am J Med</i>. 2004;117(4):279-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15308440/pubmed" id="15308440" target="_blank">15308440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551726">
<a name="22551726"></a>Hernández-Díaz S, Smith CR, Shen A, et al; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. <i>Neurology. </i>2012;78(21):1692-1699. doi:10.1212/WNL.0b013e3182574f39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22551726/pubmed" id="22551726" target="_blank">22551726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?. <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.2018">
<a name="Hoffman.2018"></a>Hoffman RS, Weinhouse GL. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22730257">
<a name="22730257"></a>Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: Lamotrigine, topiramate, and gabapentin. <i>Birth Defects Res A Clin Mol Teratol.</i> 2012;94(8):599-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22730257/pubmed" id="22730257" target="_blank">22730257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR. Alcohol use disorder: pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.2018">
<a name="Holt.2018"></a>Holt SR, Tetrault JM. Alcohol withdrawl: Ambulatory management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 8, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31205109">
<a name="31205109"></a>Hui CH, Leung JK, Chang RS, Shea YF. Reversible dysphagia due to gabapentin-induced jaw myoclonus. <i>Chin Med J (Engl)</i>. 2019;132(12):1485‐1486. doi:10.1097/CM9.0000000000000271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31205109/pubmed" id="31205109" target="_blank">31205109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30128217">
<a name="30128217"></a>Jackson CD, Clanahan MJ, Joglekar K, Decha-Umphai ST. Hold the gaba: a case of gabapentin-induced hepatotoxicity. <i>Cureus</i>. 2018;10(3):e2269. doi:10.7759/cureus.2269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30128217/pubmed" id="30128217" target="_blank">30128217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17360149">
<a name="17360149"></a>Jatzko A, Stegmeier-Petroianu A, Petroianu GA. Alpha-2-delta ligands for singultus (hiccup) treatment: three case reports. <i>J Pain Symptom Manage.</i> 2007;33(6):756-760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17360149/pubmed" id="17360149" target="_blank">17360149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Johnson.2018">
<a name="Johnson.2018"></a>Johnson BA. Pharmacotherapy for alcohol use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16709503">
<a name="16709503"></a>Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. <i>Eur J Dermatol</i>. 2006;16(3):311-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16709503/pubmed" id="16709503" target="_blank">16709503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21479999">
<a name="21479999"></a>Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? <i>Curr Pain Headache Rep</i>. 2011;15(3):164-169. doi:10.1007/s11916-011-0199-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/21479999/pubmed" id="21479999" target="_blank">21479999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8648543">
<a name="8648543"></a>Khurana DS, Riviello J, Helmers S, et al. Efficacy of gabapentin therapy in children with refractory partial seizures. <i>J Pediatr.</i> 1996;128(6):829-833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8648543/pubmed" id="8648543" target="_blank">8648543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kobrin.2018">
<a name="Kobrin.2018"></a>Kobrin SM. Uremic pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28759492">
<a name="28759492"></a>Kohse EK, Hollmann MW, Bardenheuer HJ, Kessler J. Chronic hiccups: an underestimated problem. <i>Anesth Analg</i>. 2017;125(4):1169-1183. doi:10.1213/ANE.0000000000002289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28759492/pubmed" id="28759492" target="_blank">28759492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25864854">
<a name="25864854"></a>Koncicki HM, Brennan F, Vinen K, Davison SN. An approach to pain management in end stage renal disease: considerations for general management and intradialytic symptoms. <i>Semin Dial</i>. 2015;28(4):384-391. doi:10.1111/sdi.12372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25864854/pubmed" id="25864854" target="_blank">25864854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27881247">
<a name="27881247"></a>Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. <i>Am J Kidney Dis</i>. 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27881247/pubmed" id="27881247" target="_blank">27881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20640233">
<a name="20640233"></a>Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. <i>Pharmaceuticals (Basel)</i>. 2010;3(6):1909-1935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20640233/pubmed" id="20640233" target="_blank">20640233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062788">
<a name="17062788"></a>Kristensen JH, Ilett KF, Hackett LP, Kohan R. Gabapentin and breastfeeding: a case report. <i>J Hum Lact</i>. 2006;22(4):426-428. doi:10.1177/0890334406293421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17062788/pubmed" id="17062788" target="_blank">17062788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900801">
<a name="12900801"></a>Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. <i>Am J Kidney Dis</i>. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12900801/pubmed" id="12900801" target="_blank">12900801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10360150">
<a name="10360150"></a>Labbate LA, Rubey RN. Gabapentin-induced ejaculatory failure and anorgasmia. <i>Am J Psychiatry</i>. 1999;156(6):972. doi:10.1176/ajp.156.6.972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10360150/pubmed" id="10360150" target="_blank">10360150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11774985">
<a name="11774985"></a>Lasso-de-la-Vega MC, Zapater P, Such J, Pérez-Mateo M, Horga JF. Gabapentin-associated hepatotoxicity. <i>Am J Gastroenterol</i>. 2001;96(12):3460‐3462. doi:10.1111/j.1572-0241.2001.05357.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/11774985/pubmed" id="11774985" target="_blank">11774985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23053645">
<a name="23053645"></a>Lavigne JE, Heckler C, Mathews JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. <i>Breast Cancer Res Treat</i>. 2012;136(2):479-486. doi:10.1007/s10549-012-2251-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23053645/pubmed" id="23053645" target="_blank">23053645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8603631">
<a name="8603631"></a>Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. <i>Epilepsia</i>. 1996;37(1):87‐90. doi:10.1111/j.1528-1157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8603631 /pubmed" id="8603631 " target="_blank">8603631 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20948434">
<a name="20948434"></a>Lee SH, Baig M, Rusciano V, Dutcher JP. Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. <i>J</i>
<i>Immunother</i>. 2010;33(9):1010-1013. doi:10.1097/CJI.0b013e3181fb65fd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20948434/pubmed" id="20948434" target="_blank">20948434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lembo.2018">
<a name="Lembo.2018"></a>Lembo AJ. Hiccups. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27450233">
<a name="27450233"></a>Li L, Xu L, Wu J, Dong L, Zhao S, Zheng Q. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. <i>Eur J Clin Pharmacol</i>. 2016;72(9):1051-1058. doi:10.1007/s00228-016-2090-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27450233/pubmed" id="27450233" target="_blank">27450233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12883229">
<a name="12883229"></a>Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. <i>Ther Drug Monit</i>. 2003;25(4):457-462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12883229/pubmed" id="12883229" target="_blank">12883229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15957120">
<a name="15957120"></a>Lipson J, Lavoie S, Zimmerman D. Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. <i>Am J Kidney Dis</i>. 2005;45(6):e100‐e104. doi:10.1053/j.ajkd.2005.02.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15957120/pubmed" id="15957120" target="_blank">15957120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20531055">
<a name="20531055"></a>Lopez PR, Rachael T, Leicht S, Smalligan RD. Gabapentin-induced delusions of parasitosis. <i>South Med J</i>. 2010;103(7):711‐712. doi:10.1097/SMJ.0b013e3181e1e449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20531055/pubmed" id="20531055" target="_blank">20531055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332723">
<a name="19332723"></a>Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. <i>J Clin Oncol</i>. 2009;27(17):2831-2837. doi:10.1200/JCO.2008.19.6253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19332723/pubmed" id="19332723" target="_blank">19332723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27737595">
<a name="27737595"></a>Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. <i>Expert Opin Drug Saf</i>. 2017;16(1):77‐87. doi:10.1080/14740338.2017.1248399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27737595/pubmed" id="27737595" target="_blank">27737595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24190578">
<a name="24190578"></a>Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. <i>JAMA Intern Med</i>. 2014;174(1):70-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24190578/pubmed" id="24190578" target="_blank">24190578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27206757">
<a name="27206757"></a>Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. <i>J Am Acad Dermatol</i>. 2016;75(3):619-625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27206757/pubmed" id="27206757" target="_blank">27206757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34330877">
<a name="34330877"></a>McPherson C. Gabapentin in infants: Critical evaluation of a novel sedative/analgesic medication. <i>Neonatal Netw</i>. 2021;40(4):267-272. doi:10.1891/11-T-687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/34330877/pubmed" id="34330877" target="_blank">34330877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehrizi.2019">
<a name="Mehrizi.2019"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and myasthenia gravis (a reference for health care professionals), Indiana University School of Medicine (Department of Neurology), 2012. https://www.myasthenia.org/portals/0/draft_medications_and_myasthenia_gravis_for_MGFA_website_8%2010%2012.pdf. Accessed July 31, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23093831">
<a name="23093831"></a>Menon M. Gabapentin in the treatment of persistent hiccups in advanced malignancy. <i>Indian J Palliat Care. </i>2012;18(2):138-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23093831/pubmed" id="23093831" target="_blank">23093831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26721643">
<a name="26721643"></a>Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. <i>Ann Pharmacother</i>. 2016;50(3):229-233. doi:10.1177/1060028015620800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26721643/pubmed" id="26721643" target="_blank">26721643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21745832">
<a name="21745832"></a>Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. <i>Am J Hosp Palliat Care</i>. 2012;29(3):177-182. doi:10.1177/1049909111412539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/21745832/pubmed" id="21745832" target="_blank">21745832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189556">
<a name="31189556"></a>Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. <i>BMJ</i>. 2019;365:l2147. doi:10.1136/bmj.l2147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31189556/pubmed" id="31189556" target="_blank">31189556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28611774">
<a name="28611774"></a>Montañez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. <i>Front Immunol</i>. 2017;8:614. doi:10.3389/fimmu.2017.00614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28611774/pubmed" id="28611774" target="_blank">28611774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24771480">
<a name="24771480"></a>Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. <i>Cochrane </i>
<i>Database Syst Rev</i>. 2014;(4):CD007938. doi:10.1002/14651858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24771480/pubmed" id="24771480" target="_blank">24771480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224688">
<a name="33224688"></a>Moore TA. Ambulatory detoxification in alcohol use disorder and opioid use disorder. <i>Ment Health Clin</i>. 2020;10(6):307-316. doi:10.9740/mhc.2020.11.307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/33224688/pubmed" id="33224688" target="_blank">33224688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10866495">
<a name="10866495"></a>Moretti R, Torre P, Antonello RM, Nasuelli D, Cazzato G. Treatment of chronic hiccups: new perspectives. <i>Eur J Neurol</i>. 1999;6(5):617-620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10866495/pubmed" id="10866495" target="_blank">10866495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998440">
<a name="14998440"></a>Moretti R, Torre P, Antonello RM, Ukmar M, Cazzato G, Bava A. Gabapentin as a drug therapy of intractable hiccup because of vascular lesion: a three-year follow up. <i>Neurologist</i>. 2004;10(2):102-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14998440/pubmed" id="14998440" target="_blank">14998440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28716783">
<a name="28716783"></a>Mostacci B, Poluzzi E, D'Alessandro R, Cocchi G, Tinuper P; ESPEA Study Group. Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. <i>J Neurol Neurosurg Psychiatry</i>. 2018;89(2):223-224. doi:10.1136/jnnp-2017-316143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28716783/pubmed" id="28716783" target="_blank">28716783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19485969">
<a name="19485969"></a>Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. <i>Alcohol Clin Exp Res</i>. 2009;33(9):1582-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19485969/pubmed" id="19485969" target="_blank">19485969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17679749">
<a name="17679749"></a>Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyan S, Mohseni M. Gabapentin: a promising drug for the treatment of uremic pruritus. <i>Saudi J Kidney Dis Transpl</i>. 2007;18(3):378-381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17679749/pubmed" id="17679749" target="_blank">17679749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2013">
<a name="NICE.2013"></a>National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. https://www.nice.org.uk/guidance/CG173. Published November 2013. Updated April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]. https://www.nice.org.uk/guidance/cg183. Updated November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670414">
<a name="16670414"></a>Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. <i>JAMA</i>. 2006;295(17):2057-2071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16670414/pubmed" id="16670414" target="_blank">16670414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neurontin.2020.04">
<a name="Neurontin.2020.04"></a>Neurontin (gabapentin) [prescribing information]. New York, NY: Parke-Davis; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9054293">
<a name="9054293"></a>Nissani M, Sanchez EA. Stuttering caused by gabapentin. <i>Ann Intern Med</i>. 1997;126(5):410. doi:10.7326/0003-4819-126-5-199703010-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9054293/pubmed" id="9054293" target="_blank">9054293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27043168">
<a name="27043168"></a>Nofal E, Farag F, Nofal A, Eldesouky F, Alkot R, Abdelkhalik Z. Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. <i>J Dermatolog Treat</i>. 2016;27(6):515-519. doi:10.3109/09546634.2016.1161161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27043168/pubmed" id="27043168" target="_blank">27043168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26382310">
<a name="26382310"></a>North American Menopause Society (NAMS). Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. <i>Menopause. </i>2015;22(11):1155-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26382310/pubmed" id="26382310" target="_blank">26382310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37252752">
<a name="37252752"></a>North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/37252752/pubmed" id="37252752" target="_blank">37252752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11479399">
<a name="11479399"></a>Norton JW. Gabapentin withdrawal syndrome. <i>Clin Neuropharmacol</i>. 2001;24(4):245-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/11479399/pubmed" id="11479399" target="_blank">11479399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19799624">
<a name="19799624"></a>Ohman I, Tomson T. Abstracts of the 28th International Epilepsy Congress. Budapest, Hungary. June 29-July 1, 2009. <i>Epilepsia</i>. 2009;50 Suppl 10:1-182. doi:10.1111/j.1528-1167.2009.02320.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19799624/pubmed" id="19799624" target="_blank">19799624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16190933">
<a name="16190933"></a>Ohman I, Vitols S, Tomson T. Pharmacokinetics of Gabapentin During Delivery, in the Neonatal Period, and Lactation: Does a Fetal Accumulation Occur During Pregnancy? <i>Epilepsia</i>. 2005;46(10):1621-1624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16190933/pubmed" id="16190933" target="_blank">16190933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36777316">
<a name="36777316"></a>Olopoenia A, Camelo-Castillo W, Qato DM, et al. Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: a nested case-control study. <i>Lancet Reg Health Am</i>. 2022;13:100302. doi:10.1016/j.lana.2022.100302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/36777316/pubmed" id="36777316" target="_blank">36777316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29491754">
<a name="29491754"></a>O'Mara KL, Islam S, Taylor JA, Solomon D, Weiss MD. Gabapentin improves oral feeding in neurologically intact infants with abdominal disorders. <i>J Pediatr Pharmacol Ther</i>. 2018;23(1):59-63. doi:10.5863/1551-6776-23.1.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/29491754/pubmed" id="29491754" target="_blank">29491754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18981399">
<a name="18981399"></a>Ong AM, Tan CS, Foo MW, Kee TY. Gabapentin for intractable hiccups in a patient undergoing peritoneal dialysis. <i>Perit Dial Int</i>. 2008;28(6):667-668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18981399/pubmed" id="18981399" target="_blank">18981399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37799214">
<a name="37799214"></a>Órfão A, Madeira D, Maia Duarte D, Galante Pereira F, Matos C. Gabapentin-induced cutaneous leukocytoclastic vasculitis: a case report. <i>Cureus</i>. 2023;15(9):e44616. doi:10.7759/cureus.44616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/37799214/pubmed" id="37799214" target="_blank">37799214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16616830">
<a name="16616830"></a>Oskay T, Karademir A, Ertürk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. <i>Epilepsy Res</i>. 2006;70(1):27‐40. doi:10.1016/j.eplepsyres.2006.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16616830/pubmed" id="16616830" target="_blank">16616830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10768633">
<a name="10768633"></a>Palomeras E, Sanz P, Cano A, Fossas P. Dystonia in a patient treated with propranolol and gabapentin. <i>Arch Neurol</i>. 2000;57(4):570‐571. doi:10.1001/archneur.57.4.570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10768633/pubmed" id="10768633" target="_blank">10768633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10440462">
<a name="10440462"></a>Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. <i>J Clin Psychopharmacol</i>. 1999;19(4):341-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10440462/pubmed" id="10440462" target="_blank">10440462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27147215">
<a name="27147215"></a>Parsons KA, Derkits ME. Visual hallucinations associated with gabapentin use. <i>Am J Health Syst Pharm</i>. 2016;73(10):631‐634. doi:10.2146/ajhp150136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27147215/pubmed" id="27147215" target="_blank">27147215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20388896">
<a name="20388896"></a>Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. <i>JAMA</i>. 2010;303(14):1401-1409. doi:10.1001/jama.2010.410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20388896/pubmed" id="20388896" target="_blank">20388896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32870921">
<a name="32870921"></a>Patorno E, Hernandez-Diaz S, Huybrechts KF, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. <i>PLoS Med</i>. 2020;17(9):e1003322. doi:10.1371/journal.pmed.1003322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/32870921/pubmed" id="32870921" target="_blank">32870921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14655224">
<a name="14655224"></a>Penumalee S, Kissner PZ, Migdal SD. Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. <i>Am J Kidney Dis</i>. 2003;42(6):E3‐E5. doi:10.1053/j.ajkd.2003.08.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14655224/pubmed" id="14655224" target="_blank">14655224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10777198">
<a name="10777198"></a>Petroianu G, Hein G, Stegmeier-Petroianu A, Bergler W, Rüfer R. Gabapentin "add-on therapy" for idiopathic chronic hiccup (ICH). <i>J Clin Gastroenterol</i>. 2000;30(3):321-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10777198/pubmed" id="10777198" target="_blank">10777198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25553600">
<a name="25553600"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al; International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25553600/pubmed" id="25553600" target="_blank">25553600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644468">
<a name="15644468"></a>Pina MA, Modrego PJ. Dystonia induced by gabapentin. <i>Ann Pharmacother</i>. 2005;39(2):380‐382. doi:10.1345/aph.1E503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15644468/pubmed" id="15644468" target="_blank">15644468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24149930">
<a name="24149930"></a>Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M; Breeze 3 Investigators. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. <i>Menopause.</i> 2014;21(6):567-573.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24149930/pubmed" id="24149930" target="_blank">24149930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26416344">
<a name="26416344"></a>Pongcharoen P, Fleischer AB Jr. An evidence-based review of systemic treatments for itch. <i>Eur J Pain</i>. 2016;20(1):24-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26416344/pubmed" id="26416344" target="_blank">26416344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999003">
<a name="27999003"></a>Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. <i>Diabetes Care. </i>2017;40(1):136-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27999003/pubmed" id="27999003" target="_blank">27999003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581957">
<a name="14581957"></a>Porzio G, Aielli F, Narducci F, et al. Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. <i>N Z Med J</i>. 2003;116(1182):1-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14581957/pubmed" id="14581957" target="_blank">14581957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20414106">
<a name="20414106"></a>Porzio G, Aielli F, Verna L, Aloisi P, Galletti B, Ficorella C. Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. <i>Clin Neuropharm. </i>2010;33(4):179-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20414106/pubmed" id="20414106" target="_blank">20414106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pressler.1998">
<a name="Pressler.1998"></a>Pressler KL, Jabbour JT, Rose DF, et al. Gabapentin and aggression in pediatric patients: A review of the literature. <i>Journal of Pediatric Pharmacy Practice.</i> 1998;3(2):100-105.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34965987">
<a name="34965987"></a>Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. <i>Neurology</i>. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/34965987/pubmed" id="34965987" target="_blank">34965987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307046">
<a name="11307046"></a>Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. <i>Clin Neuropharmacol</i>. 2001;24(2):103‐105. doi:10.1097/00002826-200103000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/11307046/pubmed" id="11307046" target="_blank">11307046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17089397">
<a name="17089397"></a>Raju PM, Walker RW, Lee MA. Dyskinesia induced by gabapentin in idiopathic Parkinson's disease. <i>Mov Disord</i>. 2007;22(2):288‐289. doi:10.1002/mds.21209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17089397/pubmed" id="17089397" target="_blank">17089397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30992804">
<a name="30992804"></a>Rakoski M, Goyal P, Spencer-Safier M, Weissman J, Mohr G, Volk M. Pain management in patients with cirrhosis. <i>Clin Liver Dis (Hoboken)</i>. 2018;11(6):135-140. doi:10.1002/cld.711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30992804/pubmed" id="30992804" target="_blank">30992804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19212903">
<a name="19212903"></a>Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. <i>Ren Fail</i>. 2009;31(2):85-90. doi:10.1080/08860220802595476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19212903/pubmed" id="19212903" target="_blank">19212903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16816054">
<a name="16816054"></a>Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. <i>Obstet Gynecol. </i>2006;108(1):41-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16816054/pubmed" id="16816054" target="_blank">16816054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301420">
<a name="29301420"></a>Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder.<i> Am J Psychiatry</i>. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/29301420/pubmed" id="29301420" target="_blank">29301420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30844853">
<a name="30844853"></a>Rissardo JP, Caprara ALF. Gabapentin-Associated Urinary Incontinence: A Case Verified by Rechallenge. <i>Clin Neuropharmacol</i>. 2019;42(3):91‐93. doi:10.1097/WNF.0000000000000334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30844853/pubmed" id="30844853" target="_blank">30844853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37755242">
<a name="37755242"></a>Rissardo JP, Medeiros Araujo de Matos U, Fornari Caprara AL. Gabapentin-associated movement disorders: a literature review. <i>Medicines (Basel)</i>. 2023;10(9):52. doi:10.3390/medicines10090052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/37755242/pubmed" id="37755242" target="_blank">37755242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35103995">
<a name="35103995"></a>Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. <i>Hepatology</i>. 2022;76(3):819-853. doi:10.1002/hep.32378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/35103995/pubmed" id="35103995" target="_blank">35103995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24063872">
<a name="24063872"></a>Rohman L, Hebron A. Acute dystonic reaction caused by gabapentin. <i>J Emerg Med</i>. 2014;46(3):e89. doi:10.1016/j.jemermed.2013.08.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24063872/pubmed" id="24063872" target="_blank">24063872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24284851">
<a name="24284851"></a>Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. <i>Pain Physician</i>. 2013;16(6):705-714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24284851/pubmed" id="24284851" target="_blank">24284851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26644543">
<a name="26644543"></a>Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. <i>J Clin Oncol</i>. 2016;34(6):611-635. doi:10.1200/JCO.2015.64.3809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26644543/pubmed" id="26644543" target="_blank">26644543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22951084">
<a name="22951084"></a>Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2012;380(9853):1583-1589. doi:10.1016/S0140-6736(12)60776-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22951084/pubmed" id="22951084" target="_blank">22951084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28638303">
<a name="28638303"></a>Sacha GL, Foreman MG, Kyllonen K, Rodriguez RJ. The use of gabapentin for pain and agitation in neonates and infants in a neonatal ICU. <i>J Pediatr Pharmacol Ther</i>. 2017;22(3):207-211. doi:10.5863/1551-6776-22.3.207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/28638303/pubmed" id="28638303" target="_blank">28638303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18382181">
<a name="18382181"></a>Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options. <i>Clin Neuropharmacol</i>. 2008;31(2):93‐96. doi:10.1097/WNF.0b013e31806ad6cb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18382181/pubmed" id="18382181" target="_blank">18382181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20049491">
<a name="20049491"></a>Saletu M, Anderer P, Saletu-Zyhlarz GM, et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. <i>J Neural Transm (Vienna).</i> 2010;117(4):463-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20049491/pubmed" id="20049491" target="_blank">20049491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171730">
<a name="19171730"></a>Sandercock D, Cramer M, Wu J, Chiang YK, Biton V, Heriter M. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. <i>Diabetes Care</i>. 2009;32(2):e20. doi:10.2337/dc08-1450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19171730/pubmed" id="19171730" target="_blank">19171730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22497967">
<a name="22497967"></a>Sandercock D, Cramer M, Biton V, Cowles VE. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. <i>Diabetes Res Clin Pract</i>. 2012;97(3):438-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22497967/pubmed" id="22497967" target="_blank">22497967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santen.2018">
<a name="Santen.2018"></a>Santen RJ, Loprinzi CL, Casper RF. Menopausal hot flashes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21658302">
<a name="21658302"></a>Scaparrotta A, Verrotti A, Consilvio NP, et al. Pathogenesis and clinical approaches to anticonvulsant hypersensitivity syndrome: current state of knowledge. <i>Int J Immunopathol Pharmacol</i>. 2011;24(2):277‐284. doi:10.1177/039463201102400201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/21658302/pubmed" id="21658302" target="_blank">21658302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2018">
<a name="Schachter.2018"></a>Schachter SC. Anti-seizure drugs: mechanism of action, pharmacology and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 11, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25387462">
<a name="25387462"></a>Scholl JH, van Eekeren R, van Puijenbroek EP. Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients. <i>Br J Clin Pharmacol</i>. 2015;79(5):870‐871. doi:10.1111/bcp.12548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25387462/pubmed" id="25387462" target="_blank">25387462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18090442">
<a name="18090442"></a>Schuchmann JA, Browne BA. Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. <i>Am J Phys Med Rehabil</i>. 2007;86(12):1013-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18090442/pubmed" id="18090442" target="_blank">18090442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082‐1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silber.2018">
<a name="Silber.2018"></a>Silber MH. Treatment of restless legs syndrome and periodic limb movement disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24940142">
<a name="24940142"></a>Souzdalnitski D, Chang AK, Guirguis M. Chorea in a chronic pain patient using gabapentin. <i>Ochsner J</i>. 2014;14(2):276‐278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24940142/pubmed" id="24940142" target="_blank">24940142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spaia.2009">
<a name="Spaia.2009"></a>Spaia SA, Tersi M, Sidiropoulou M, Askepidis N, Pazarloglou M, Iliadi V. Management of neuropathic pain in dialysis patients: an effective approach with gabapentin. <i>Dialysis &amp; Transplantation</i>. 2009;38(9):1-3. doi:10.1002/dat.20348</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2018">
<a name="Stein.2018"></a>Stein MB, Taylor CT. Approach to treating social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33130590">
<a name="33130590"></a>Sudana P, Basu S, Shanbhag SS. Oral mucous membrane grafts for total symblepharon and lid margin keratinisation post Stevens-Johnson syndrome. <i>BMJ Case Rep</i>. 2020;13(10):e239383. doi:10.1136/bcr-2020-239383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/33130590/pubmed" id="33130590" target="_blank">33130590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tauben.2020">
<a name="Tauben.2020"></a>Tauben D. Pharmacologic management of chronic non-cancer pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30968430">
<a name="30968430"></a>Tellor KB, Ngo-Lam R, Badran D, Armbruster AL, Schwarze MW. A rare case of a gabapentin-induced cardiomyopathy. <i>J Clin Pharm Ther</i>. 2019;44(4):644‐646. doi:10.1111/jcpt.12840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30968430/pubmed" id="30968430" target="_blank">30968430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36193017">
<a name="36193017"></a>Tomson T, Battino D, Bromley R, et al. Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force. <i>Epileptic Disord</i>. 2022;24(6):1020-1032. doi:10.1684/epd.2022.1492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/36193017/pubmed" id="36193017" target="_blank">36193017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31782407">
<a name="31782407"></a>Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. <i>Epileptic Disord</i>. 2019;21(6):497-517. doi:10.1684/epd.2019.1105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/31782407/pubmed" id="31782407" target="_blank">31782407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19302896">
<a name="19302896"></a>Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. <i>Clin Ther</i>. 2009;31(2):221-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19302896/pubmed" id="19302896" target="_blank">19302896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15898970">
<a name="15898970"></a>Tran KT, Hranicky D, Lark T, Jacob NJ. Gabapentin withdrawal syndrome in the presence of a taper. <i>Bipolar Disord</i>. 2005;7(3):302-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15898970/pubmed" id="15898970" target="_blank">15898970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565043">
<a name="17565043"></a>Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. <i>Ann Pharmacother</i>. 2007;41(7):1301‐1305. doi:10.1345/aph.1K077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17565043/pubmed" id="17565043" target="_blank">17565043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18392431">
<a name="18392431"></a>Twardowschy CA, Teive HA, Fernandes AF, Búrigo IP, Lange M, Werneck LC. Chorea due to gabapentin monotherapy in a not encephalopatic patient. <i>Arq Neuropsiquiatr</i>. 2008;66(1):107. doi:10.1590/s0004-282x2008000100029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18392431/pubmed" id="18392431" target="_blank">18392431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADOD.1">
<a name="VADOD.1"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25837494">
<a name="25837494"></a>Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. <i>Seizure</i>. 2015;28:57-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25837494/pubmed" id="25837494" target="_blank">25837494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987157">
<a name="16987157"></a>Vignatelli L, Billiard M, Clarenbach P; EFNS Task Force. EFNS guidelines on management of restless leg syndrome and periodic limb movement disorder in sleep. <i>Eur J Neurol.</i> 2006;13(10):1049-1065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16987157/pubmed" id="16987157" target="_blank">16987157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinberger.1">
<a name="Weinberger.1"></a>Weinberger SE, Saukkonen K. Evaluation and treatment of subacute and chronic cough in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weisshaar.2019">
<a name="Weisshaar.2019"></a>Weisshaar E, Szepietowski JC, Dalgard F, et al; European Dermatology Forum; European Academy of Dermatology and Venereology. European guideline on chronic pruritus. https://www.edf.one/dam/jcr:9c925c23-fa0f-4765-8592-a86a75ce0ec3/GL_Chronic_pruritus.pdf. Published 2019. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30931482">
<a name="30931482"></a>Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. <i>Acta Derm Venereol</i>. 2019;99(5):469-506. doi:10.2340/00015555-3164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30931482/pubmed" id="30931482" target="_blank">30931482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22790094">
<a name="22790094"></a>Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. <i>Acta Derm Venereol</i>. 2012;92(5):563-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22790094/pubmed" id="22790094" target="_blank">22790094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27819746">
<a name="27819746"></a>Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. <i>Cochrane Database Syst Rev</i>. 2016;11(11):CD010224. doi:10.1002/14651858.CD010224.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27819746/pubmed" id="27819746" target="_blank">27819746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12199723">
<a name="12199723"></a>Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. <i>Epilepsia</i>. 2002;43(9):983‐992. doi:10.1046/j.1528-1157.2002.01702.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12199723/pubmed" id="12199723" target="_blank">12199723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15099389">
<a name="15099389"></a>Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: response to treatment with gabapentin. <i>Br J Dermatol</i>. 2004;150(4):786-787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15099389/pubmed" id="15099389" target="_blank">15099389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7665723">
<a name="7665723"></a>Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. <i>J Clin Pharmacol</i>. 1995;35(6):622-626. doi:10.1002/j.1552-4604.1995.tb05020.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7665723/pubmed" id="7665723" target="_blank">7665723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30839320">
<a name="30839320"></a>Yeddi A, Adam O, Khalid M, et al. Myoclonus and altered mental status induced by single dose of gabapentin in a patient with end-stage renal disease: a case report and literature review. <i>Am J Ther</i>. 2019;26(6):e768‐e770. doi:10.1097/MJT.0000000000000942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/30839320/pubmed" id="30839320" target="_blank">30839320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20629833">
<a name="20629833"></a>Yilmaz S, Ceyhan AM, Baysal Akkaya V. Brachioradial pruritus successfully treated with gabapentin. <i>J Dermatol</i>. 2010;37(7):662-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20629833/pubmed" id="20629833" target="_blank">20629833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26891784">
<a name="26891784"></a>Yuan M, Zhou HY, Xiao ZL, et al. Efficacy and safety of gabapentin vs. carbamazepine in the treatment of trigeminal neuralgia: a meta-analysis. <i>Pain Pract</i>. 2016;16(8):1083-1091. doi:10.1111/papr.12406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26891784/pubmed" id="26891784" target="_blank">26891784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17938990">
<a name="17938990"></a>Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome type 1. <i>Clin Rheumatol</i>. 2008;27(3):389‐390. doi:10.1007/s10067-007-0744-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17938990/pubmed" id="17938990" target="_blank">17938990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11012313">
<a name="11012313"></a>Zylicz Z. Painful gynecomastia: an unusual toxicity of gabapentin?. <i>J Pain Symptom Manage</i>. 2000;20(1):2‐3. doi:10.1016/s0885-3924(00)00165-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/11012313/pubmed" id="11012313" target="_blank">11012313</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8483 Version 953.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
